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ABSTRACT 
Psoriasis is a common skin disorder that is characterized by thickening of the most 
superficial layer of the skin, the epidermis, and accumulation of white blood cells, 
inflammation. The exact mechanism of how psoriasis develops is still unknown. 
Several gene expression studies have been conducted on psoriatic skin. Most of 
them, however, have focused on the expression in both the epidermis and dermis 
or were analyzed by microarrays. Here we used a novel approach to decipher the 
gene expression profile of the psoriatic skin, by utilizing a more specific and 
sensitive detection of transcripts by RNA sequencing (RNA-seq), implemented 
with an improved normalization method, and combined with samples that 
contain mainly the skin layer of interest: the epidermis. RNA-seq revealed more 
accurate expression profiles in different sample types that had varying amount of 
total mRNA per cell. Comparison with previous transcriptomics studies on 
psoriasis revealed that our approach provided more information about the 
transcriptional dysregulation in the epidermis. The expression profiling of 
epidermis highlighted the involvement of innate immunity and provided, for 
example, deeper understanding about the components of NOD-like receptor 
signaling pathway and inflammasome activation in keratinocytes. Some of the 
components have been associated with psoriasis in previous studies, yet the exact 
composition and activation mechanisms of inflammasomes have remained 
unclear. Our RNA-seq findings thus strengthen the role of keratinocytes as 
modulators of inflammation in the psoriatic lesions. The improved methods and 
focused analysis might help to pinpoint the most important pathways and 
functions, including broader knowledge in the involved components, in the 
psoriatic lesions. This, in turn, might improve the production of more specific 
treatments for psoriasis. 
The psoriasis candidate gene CCHCR1 is located in the major psoriasis 
predisposition locus PSORS1, contains a psoriasis-associated risk allele *WWCC, 
and its gene product is expressed by the basal keratinocytes of the epidermis and 
has been shown to have an effect on cell proliferation and differentiation. The 
gene has two different transcription start sites and is able to encode for a peptide 
with a longer N-terminus from the transcript 1, which, however, depends upon a 
SNP that encodes for either tryptophan or stop codon, therefore either enabling 
or disabling the production of the longer protein. Here we presented association 
of the stop codon-encoding SNP (named as *Iso3) with psoriasis in family trios. 
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We detected that CCHCR1 localizes at the centrosome and P-bodies, and reported 
isoform-specific effects on the localization of the P-bodies. Our experiments 
exhibited haplotype-specific effects of CCHCR1 also on cytoskeletal organization 
and cell proliferation; functions relevant to the pathogenesis of psoriasis. 
Furthermore, our results suggest that CCHCR1 might function in EGFR-STAT3 
signaling and innate immunity, which strengthens the role of innate immunity in 
psoriasis even further. In addition, RNA-seq revealed isoform- and haplotype-
specific effects on the expression profiles of different CCHCR1 cell lines. 
Interestingly, the most dramatic changes in gene expressions were observed in 
the isoform 3 -overexpressing cells but also the Non-risk and Risk haplotypes had 
antagonistic effects. The observation that CCHCR1 influences multiple cell 
signaling pathways may result from its possible role as a centrosomal P-body 
protein, which suggests a role in post-transcriptional regulation as well as a role 
in the regulation of cell cycle. Its exact function in these cellular compartments 
and effect in psoriatic lesions remains to be studied further.  
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INTRODUCTION 
Psoriasis is a chronic inflammatory skin disease, characterized by red scaly 
plaques. The histological features include hyperproliferation and impaired 
differentiation of the keratinocytes, infiltration of inflammatory cells, and 
vascular changes. It has been considered as an autoimmune disease but recently 
it has been postulated whether it is in fact initiated by an abnormal response to 
pathogens in the skin, due to recent findings in genetics and transcriptomics, 
which support the importance of innate immunity. It is a multifactorial disease, 
including both genetic and environmental factors in the onset of the disease. The 
major susceptibility locus, PSORS1, includes the susceptibility genes HLA-C, with 
the risk allele *w6, and CCHCR1 that harbors the psoriasis-associated allele 
*WWCC. This thesis addresses some of the questions regarding suitable methods 
of RNA sequencing on psoriatic samples, transcriptional profile of the psoriatic 
epidermis, and functional role of CCHCR1 in psoriasis pathogenesis. 
13 
 
REVIEW OF THE LITERATURE 
1. Skin 
The skin covers the human body and is made up of multiple layers of tissue with 
ectodermal origin; it is our biggest organ. It is the primary interface between the 
body and the external environment and functions as a defensive barrier for the 
underlying muscles, bones, ligaments, and internal organs from physical and 
chemical trauma, pathogens, ultraviolet radiation, and prevents dehydration by 
regulating the transepidermal movement of water and electrolytes. Other 
functions include insulation, temperature regulation, sensation, and the 
production of vitamin D. It consists of three different layers (Figure 1): outermost 
layer is called the epidermis, underneath which locates the dermis, and the subcutis 
separates the skin from the inside of the body (Alberts et al., 2015). In this thesis, 
the function of the epidermis is on focus and we have used skin graft (SG) samples 
that contain less dermis than the usually used full-thickness biopsies (Figure 1). 
1.1. Epidermis 
Human epidermis (Figure 1) is a stratified squamous epithelium, consisting 
mainly (90-95%) of specialized epithelial cells: keratinocytes. It is separated from 
the dermis by the basement membrane, on top of which locates the basal layer of 
the epidermis (stratum basale). The lowermost part of the epidermis contains rete 
ridges, which are epidermal thickenings that extend downward towards the 
dermis. The epidermal stem cells and the keratinocytes that are able to proliferate 
are located at the basal layer and are connected to the basement membrane by 
hemidesmosomes. The keratinocytes leave the basal layer, at the same time 
withdrawing from the cell cycle, and differentiate during their journey through 
the epidermal layers towards the surface of the skin (Blanpain and Fuchs, 2006). 
Many factors affect the differentiation, one of the most important being the 
calcium gradient: the concentration of calcium is higher in the basal layer than in 
the following layer of the epidermis but again increases from there towards the 
surface (Leinonen et al., 2009). Melanocytes and Merkel cells are also located in 
this basal layer. The next layer is the spinous layer (stratum spinosum), in which 
the keratinocytes are connected to each other by desmosomes and under the 
microscope the cells appear spiky or “spinous”. Langerhans cells, among other 
immune cells, are located in this layer as well. On top of this layer the 
keratinocytes start producing lamellar bodies, which are secreted and form the  
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Figure 1 Structure of the skin. In the magnification illustrated the different layers of the 
epidermis with keratinocytes. In this thesis we focus on the epidermal gene expression, by 
using samples that are enriched by the epidermal skin (skin grafts). Most of the previous 
transcriptome studies on the skin have used full-thickness skin samples that contain both 
the epidermis and dermis. 
lipid-rich extracellular barrier that protects from water loss from the inside and 
external factors from the outside. The next layer is the granular layer (stratum 
granulosum), where the keratinocytes continue producing the lamellar bodies, 
forming the barrier, and appear granular because their cytoplasm contains 
keratohyalin granules. The contents of the granules affect the differentiation, and 
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thus the keratinization of the cells. They also lose their nucleus and organelles and 
become non-viable corneocytes. Thick skin in palms and soles contains next the 
clear layer (stratum lucidum), which is absent elsewhere in the body. On the top of 
the skin locates the cornified layer (stratum corneum), in which the cells are 
connected to each other by corneodesmosomes and from which the flattened 
corneocytes desquamate, thus shed off, eventually. (Lowes et al., 2014; Nemes and 
Steinert, 1999; Rao et al., 1996) 
Keratinocytes renew approximately within 6-10 weeks in the epidermis. Their 
differentiation is accompanied by large changes in gene expression, protein 
content, and cell morphology. Keratinocytes of the basal layer express large 
amounts of keratins 5 and 14 and are cylindrical in shape. During differentiation 
the cells start expressing keratins 1 and 10 and eventually become more flattened 
and tightly packed (Liu et al., 2007). Filaggrin, involucrin, and loricrin, among 
others, are markers of differentiated keratinocytes. The cornified envelope, a 
structure built of cross-linked proteins, lipids, and keratin bundles, starts to form 
beneath the cellular membrane and eventually replacing the cell membrane. 
1.2. Dermis and subcutis 
Dermis (Figure 1) is mainly composed of connective tissue, blood and lymphatic 
vessels, nerve endings, sweat and sebaceous glands, and hair follicles. It gives 
mechanical support for the skin and takes care of the needs of the epidermis. 
Connective tissue cells consist mainly of fibroblasts that secrete collagen and 
elastin fibers to their surroundings. In addition to fibroblasts, the dermis contains 
also white blood cells such as macrophages and lymphocytes. The uppermost 
(stratum papillare) layer of the dermis has fingerlike projections called papillae that 
extend toward the epidermis, interwining with the rete ridges. The lower leyer is 
called reticular dermis (stratum reticulare). Underneath the dermis is located the 
subcutis, which is mainly composed of loose connective tissue and fat cells, thus 
adipocytes. Its main function is to protect the body from hits and connect the skin 
to underlying tissues. (Breathnach, 1978) 
2. Psoriasis 
The word psoriasis comes from the Greek word psora “to itch”, which is quite an 
explanatory description of the disease. Psoriasis is a chronic inflammatory skin 
disease affecting 2–3% of people with European descent but occurring less in 
other populations such as in Asia and Africa (Roberson and Bowcock, 2010). The 
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histopathological changes in psoriatic skin include thickened spinous layer 
(acanthosis) with inward grown and elongated rete ridges (epithelial buttressing) 
and thickened cornified layer (hyperkeratosis). The keratinocytes within the 
psoriatic plaque proliferate excessively in the extended suprabasal layer 
(hyperproliferation), the granular layer is missing or abrupted (hypogranulosis), and 
the cells retain their nuclei in the cornified layer (parakeratosis). The eruption of 
the disease is associated with the infiltration of immune cells, such as neutrophilic 
leucocytes and macrophages, into the epidermis and dilation of papillary blood 
vessels in the dermis. The immune cells secrete proinflammatory cytokines, such 
as interleukins and chemokines, thus creating a “cytokine storm”. Moreover, 
psoriasis is characterized by increased turnover and altered terminal 
differentiation of the keratinocytes, including impaired degradation of 
desmosomes. The skin's barrier becomes dysfunctional and allows opportunities 
for external pathogens to enter the body (Mezentsev et al., 2014; Roberson and 
Bowcock, 2010). 
Psoriasis is a complex multifactorial disease, with genetic factors affecting the 
susceptibility but also the environmental factors (such as smoking, 
psychophysical traumas, drugs, radiation, infection, obesity, and pregnancy) play 
a pivotal role in the onset of the disease (Elder et al., 2010). It is considered as a T-
cell-mediated disease, addressing the activity of T-helper (Th)1, Th17, and Th22 
cells and regulation by regulatory T cells (Treg) (Monteleone et al., 2011). It has 
been considered as an autoimmune disease but lately it has been postulated 
whether it is in fact initiated by an abnormal response to pathogens in the skin, 
due to genetic factors (Mattozzi et al., 2016; Mattozzi et al., 2012). Moreover, the 
recent findings in genetics and transcriptomics support the importance of innate 
immunity, which is known to be hyperactivated in psoriasis (Gudjonsson et al., 
2009; Tsoi et al., 2012).  
The patients also have an increased risk of comorbid diseases, such as psoriatic 
arthritis, metabolic syndrome (or components of it), cardiovascular disorders, 
anxiety and depression, non-alcoholic fatty liver disease, lymphoma, and Crohn’s 
disease (Boehncke, 2015). It is also associated with psychological burden since the 
visibility of the disfigurations may impair the quality of life in the patients (Rapp 
et al., 1999). 
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2.1. Pathogenesis of psoriasis 
Several functional characteristics of skin contribute to its effectiveness at 
maintaining homeostasis, despite the fact that it is regularly colonized by a variety 
of organisms. Antimicrobial peptides secreted by keratinocytes contribute to this 
maintenance by forming a shield against pathogens (Figure 2a). Several immune 
cell types are also resident in the skin. They maintain the steady-state immunity, 
and are ready to respond to a variety of stimuli. Balancing the defensive 
mechanisms is important for achieving homoeostasis as disruption of any of these 
components contribute to the manifestation of dermatological diseases, such as 
psoriasis. (Stingl and Steiner, 1989) 
2.1.1. Innate immunity 
Innate immunity provides the first line of defence against infections. Most 
components of the innate immunity are present already before the onset of 
infection and are therefore not specific to a particular pathogen in the way that 
the adaptive immunity is. They include molecular components, such as 
antimicrobial peptides and the complement system, and phagocytic cells, such as 
macrophages and neutrophils that recognize classes of molecules charasteristic to 
frequently encountered pathogens (Janeway, 2005). Skin and other epithelial 
surfaces provide anatomical and physiological barriers between the external 
environment and the inside of the body. Tight junctions, connecting the 
neighbouring cells, prevent easy entry by the potential pathogens. However, 
wounds in the skin create obvious routes for infection - psoriasis can be triggered 
by many factors, including injury and trauma (Köbner phenomenon), but also by 
infections and medications et cetera. Adaptive immune system plays an 
important role in the pathogenesis of psoriasis but the initial activation of the 
innate immune system is required at first. Moreover, recent studies also address 
the critical role of the innate immune system in psoriasis susceptibility but the 
medication strategies are currently aimed at the adaptive immune responses. 
18 
 
 
Figure 2 Inflammatory components of healthy and psoriatic skin. (a) Normal epidermis 
is formed by slowly differentiating keratinocytes. Antimicrobial peptides (AMPs) may be 
stored in the granular keratinocytes, including S100A family proteins, β-defensins, 
cathelicidin (CAMP), and lipocalin 2 (LCN2). The nuclei are lost as granular keratinocytes 
differentiate to corneocytes, and a cross-linked protein membrane structure termed the 
cornified envelope is formed, between which many layers of neutral lipids are deposited, 
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producing an effective water-impermeable barrier. Steady-state immunity is maintained 
by various immune cells: the epidermis contains Langerhans cells (LCs) and the dermis 
contains resident myeloid dendritic cells (DCs). There are also nonrecirculating cutaneous 
lymphocyte antigen (CLA)+ resident memory T cells (Trm cells) in the skin but 
keratinocytes constitutively synthesize CCL27 that attracts CCR10+ CLA+ skin-homing T 
cells into healthy skin for immune surveillance. (b) The epidermis participates also in 
innate or adaptive immune responses to triggers such as injury or infection. Keratinocytes 
proliferate in response to cytokines to accelerate loss of surface keratinocytes, eliminate 
pathogens, increase synthesis of innate effector molecules such as AMPs, and direct 
migration of new T cell subsets and other immune effector cells into the skin through 
production of chemokines. Pathways for initiation and maintenance of psoriasis are 
marked in purple and red. The keratinocytes within the psoriatic plaque proliferate 
excessively, the granular layer is abrupted, and the cells retain their nuclei in the cornified 
layer. Early disease (purple): CAMP released from keratinocytes (KCs) can bind to nucleic 
acids to activate plasmacytoid DCs to release IFN-α/β. CAMP/RNA complexes can also 
activate resident myeloid DCs to produce IL-12 and IL-23, key psoriatic cytokines. 
Extracellular DNA has been shown in the epidermis in association with neutrophil 
extracellular traps (NETs) and the role of mast cells has been implicated as well. Chronic 
psoriasis (red): The major pathogenic pathway in psoriasis occurs when mature dermal 
DCs and inflammatory myeloid DCs produce cytokines such as IL-23 and IL-12. These 
cytokines activate T helper and cytotoxic cells: T17, T1, and T22, to contribute to the 
cytokine milieu and further act on keratinocytes. Neutrophils are recruited to the 
epidermis and amplification loop retains chronic inflammation. Remade and modified 
from Lowes et al. 2014. 
2.1.1.1. Barrier function 
The stratum corneum maintains the uppermost epidermal barrier between the 
environment and the human body and is composed of terminally differentiated 
keratinocytes and extracellular lipids, such as ceramides (CER), cholesterol, and 
free fatty acids. The concentration and composition of ceramides is changed in 
psoriatic skin, which is suggested to affect the maintenance of skin barrier 
function and regulation of proliferation, differentiation, and apoptosis of 
keratinocytes (Borodzicz et al., 2016; Holleran et al., 2006). Corneodesmosomes 
also play a role in the pathogenesis of psoriasis; a reduced degradation of 
corneodesmosomal proteins (such as CDSN) in psoriatic lesions has been 
suggested, plausibly affecting the persistence of corneodesmosomes in the 
stratum corneum (Simon et al., 2008).  
Tight junctions maintain the second physiological barrier in the stratum 
granulosum (Bazzoni and Dejana, 2002). Considering the impressively high 
amount of microbes constantly in contact with our skin, one of the functions of 
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the physical barriers is to segregate the immune receptors (and cells) from skin 
surface ligands to avoid activation of the receptors under non-pathologic 
conditions. Altered expression of several tight junction proteins have been 
observed in psoriasis lesional skin but their biological relevance in the 
pathogenesis of the disease is still unclear (Brandner et al., 2015).  
2.1.1.2. Pattern recognition receptor families and inflammasomes 
The activation of innate immunity relies on a limited set of pattern recognition 
receptors (PRRs) that recognize specific pathogen (PAMPs) or damage-associated 
molecular patterns (DAMPs) (Cao, 2016). The PAMPs are commonly present in 
microbes but not in mammals, whereas DAMPs are often cytosolic or nuclear 
molecules (DNA, RNA, S100 proteins etc.) that are released outside of the cell, e.g. 
upon exocytosis, injury, or necrosis. Activated PRRs trigger an inflammatory 
response leading to the efficient destruction of the invading pathogens, which 
include the secretion of cytokines, the induction of antimicrobial peptides (AMPs), 
pyroptotic cell death and the recruitment of phagocytic cells. The main PRR 
families are the Toll-Like receptors (TLRs), the NOD-Like receptors (NLRs), the 
RIG-I-Like receptors (RLRs), cytosolic DNA sensors (CDS), and the C-type lectin 
receptors (CLRs). They also play a central role in the activation of inflammasomes 
and autophagy (Schaefer, 2014). Inflammasomes are infection or stress-activated 
cytoplasmic protein complexes that consist of a NOD-like receptor (NLR) protein, 
caspase 1 (CASP1) (sometimes also CASP5), and the adaptor protein pyd and card 
domain-containing protein (PYCARD), which is the key component of the 
inflammasomes. The complex regulates the activity of CASP1, which is required 
for the processing and maturation of inflammatory cytokines; interleukins IL-1 
and IL-18. The exact composition of the inflammasome depends on the activator 
that initiates its assembly (Latz et al., 2013). They have been studied extensively 
in immune cells, such as macrophages and langerhans cells, but many NLR 
inflammasome complexes are also expressed in human epithelial cells, such as 
keratinocytes.  
The expression of several AMPs, whose expression can be triggered by the PPRs, 
is strongly increased in psoriatic plaques (Figure 2b) (Guttman-Yassky et al., 2011). 
The induction and early events of psoriasis have been suggested to begin with 
events involving the innate immunity (Figure 2b, purple). Dendritic cells (DCs) 
are professional antigen presenting cells that function as a link between the innate 
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and adaptive immune system, providing protection against commensals and 
invading pathogens. Keratinocytes, dermal fibroblasts, and immune cells secrete 
inflammatory cytokines under pathological skin conditions, which affects the 
activation and maturation of different DC populations, including Langerhans 
cells (LC) and dermal DC (Said 2015). Langerhans cells (LCs) are the only 
dendritic cells found in the epidermis during the steady-state and are considered 
as the first immunological barrier of the skin. Yet, their role in psoriasis has 
remained unclear. In psoriasis, injury or infection at the epidermis causes 
upregulated production of the AMP cathelicidin (CAMP) by keratinocytes 
(Lowes et al., 2014). CAMP can form aggregates with extracellular self-DNA that 
can activate TLR9 on the plasmacytoid DCs, thereby triggering interferon type I 
(IFN-α and -β) production (Lande et al., 2007; Nestle et al., 2005). CAMP/RNA 
complexes activate plasmacytoid DCs through TLR7, and myeloid DCs through 
TLR8, which are activated by type I IFNs as well. The myeloid DCs then activate 
T cells and thereby initiating the massive production of cytokines.  
Transforming growth factor alpha (TGF-α) is induced in psoriasis and has been 
shown to affect the expression and function of TLR5 and TLR9 also in 
keratinocytes (de Koning et al., 2012b). Furthermore, the topical application of 
imiquimod, a ligand for TLR7 and TLR8, has been shown to induce psoriasis (Wu 
et al., 2004). TLR7 and TLR8 signaling leads to a type I IFN response and might 
affect the IL-23/IL-17 axis, which have been implicated in psoriasis as well 
(Ladoyanni and Nambi, 2005; van der Fits et al., 2009). In addition, CLR dectin-1 
expression is increased in the epidermis of psoriatic lesions and its signaling 
stimulates immune cells to produce antifungal AMPs, which are highly expressed 
in psoriatic lesions (de Koning et al., 2010).  
CAMP was also reported to function in keratinocytes, where it neutralizes 
cytosolic DNA (Dombrowski et al., 2011). Cytosolic DNA could induce IL-1β 
secretion, thus triggering absent in melanoma 2 (AIM2) -dependent 
inflammasome activation, and is abundant in psoriatic lesions.  AIM2 was also 
found upregulated in psoriatic lesions but CAMP could block the AIM2-
dependent inflammasome activation. NLRP1-dependent inflammasome has been 
also recognized in psoriasis susceptibility (Ekman et al., 2014). Psoriatic 
keratinocytes have been shown to have increased sensitivity also to viral RNA 
intermediates, enhanced by IFN-α, by inducing expression of cytosolic innate 
RNA receptors, such as retinoic acid-induced gene-I (RIG-I) and MDA5 (Prens et 
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al., 2008). In addition, increased IL-18 expression has been reported by 
keratinocytes from psoriatic lesions (Rasmy et al., 2011). Neutrophils are crucial 
for clearing bacterial infections and extracellular DNA has been shown in the 
epidermis in association with neutrophil extracellular traps (NETs), which are 
networks of extracellular fibers that bind pathogens. The role of mast cells has 
been implicated as well (Kumar and Sharma, 2010), which further supports this 
role of innate immunity in the initiation of psoriasis. 
2.1.2. Adaptive immunity 
The adaptive immune system is composed of highly specialized cells and 
processes that eliminate or prevent pathogen growth, creating immunological 
memory. The major components of adaptive immunity are lymphocytes that 
produce antibodies, cytokines, and other molecules. It normally responds only to 
foreign antigens, thus being capable of self/nonself recognition. Adaptive 
immunity is not independent of innate immunity, which initially activates it and 
the two systems collaborate in eliminating the pathogen. Two major types of cells 
mediate the immune response: lymphocytes and antigen-presenting cells. 
Lymphocytes can be divided into two groups: B lymphocytes that express 
antibodies in their surfaces and T lymphocytes that express T cell receptors via 
which they recognize antigens that are bound to major histocompatibility 
complex (MHC) molecules. MHC I molecules can be presented basically by any 
nucleated cells (such as keratinocytes), whereas MHC II molecules are expressed 
by antigen-expressing cells (such as machrophages, B lymphocytes, and DCs) 
(Janeway, 2005). 
T lymphocytes, especially T helper (Th) 17 and Th1 cells, are heavily present in 
psoriatic lesions (Lowes et al., 2007; Lowes et al., 2014). Moreover, tumor necrosis 
factor α (TNF-α) and inducible nitric oxide synthase (iNOS) -producing 
inflammatory DCs (TIP-DCs) and other inflammatory cells, such as macrophages, 
massively infiltrate to psoriatic skin (Harden et al., 2015a).  Figure 2b illustrates 
(with red markings) a current pathogenic model of adaptive immunity in 
psoriatic lesions (Lowes et al., 2014). T cell priming is instructed by IL-12 and IL-
23, which appear to be produced mainly from myeloid DC subsets in the skin. It 
was first revealed that IFN-γ-producing T cells, labelled as Th1 cells, are 
massively increased in psoriatic lesions (Lew et al., 2004). The T cells in psoriatic 
lesions also produce IL-17 (Th17) and IL-22 (Th22). There are also CD8+ T cell 
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populations in the lesions that make the same range of cytokines, which have been 
termed as Tc1, Tc17, and Tc22. In addition, γδ T cells have been found to be IL-
17-producing cells in psoriasis (Keijsers et al., 2014). It has also been suggested 
that mast cells and neutrophils, which are part of the innate immunity system, are 
the predominant cell types producing IL-17 in skin (Lin et al., 2011). Furthermore, 
skin is not merely a physical barrier but also a component of the lymphatic system, 
called as skin-associated lymphoid tissue (SALT). The chronic disease activity 
may be supported also by mature DCs (DC-LAMP+) that form cellular clusters 
with T cells in the dermis, a structure that can be considered as a form of induced 
SALT (iSALT) or tertiary lymphoid tissue (Egawa and Kabashima, 2011; Lowes et 
al., 2014). 
Keratinocytes respond to the cytokines produced by each of these T cell subsets 
by upregulating the transcription of mRNAs encoding for numerous 
inflammatory products (Lowes et al., 2014; Nograles et al., 2008). Chronic T cell 
activation persists because the induced keratinocyte products have the ability to 
feedback on immune cells in the skin. The production of chemokines by 
keratinocytes is proposed to be important for the attraction of leukocyte subsets, 
such as neutrophils and myeloid DCs, which have relatively short life spans. 
Signal transducer and activator of transcription 3 (STAT3) is phosphorylated and 
activated in psoriatic lesions (Andres et al., 2013). It is important in the signaling 
pathways of several cytokines, such as IL-6, IL-10, IL-22, and IL-23 and STAT3 
signaling can directly modulate epidermal hyperplasia (Tarutani et al., 2013). 
Moreover, it has been also reported in psoriatic lesions that IL-22 upregulates the 
expression of keratin 17 (KRT17), a hallmark and suggested autoantigen of 
psoriasis, in a STAT3-dependent manner (Zhang et al., 2012). However, as STAT3 
is required for signaling through the IL-23R, it is essential for Th17 polarization 
(Harris et al., 2007) and it is possible that psoriasis-associated mutations in STAT3 
(Tsoi et al., 2012) affect its effects on Th17 polarization. The main cell types 
involved in psoriasis and mentioned here above are collected in Table 1. 
2.2. Genetics 
Chromosomal regions harboring genetic association with psoriasis were initially 
entitled PSORS (psoriasis-susceptibility) loci. There are at least 15 different 
PSORS loci (Figure 3) that can be found from the Online Mendelian Inheritance 
in Man (OMIM), mainly identified through linkage analysis of multiply affected 
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psoriasis families and genome-wide association studies (GWAS) (Bowcock and 
Cookson, 2004; Ellinghaus et al., 2010; Harden et al., 2015b; Lowes et al., 2014; 
Marrakchi et al., 2011; Setta-Kaffetzi et al., 2014). The susceptibility gene or genes 
for most PSORS loci is still uncertain. The advances in methods and techniques in 
association studies, however, have enriched the understanding of the genetics of 
psoriasis.  
Table 1 Cell types involved in psoriasis 
Cell type Location Cytokines and AMPs 
Epidermal cells   
Keratinocytes Epidermis IFN-γ, TNF-α , IL-1, IL-6, IL-8, IL-18, 
CAMP 
Stromal cells   
Fibroblasts Dermis IL-1 
Dendritic cells   
Myeloid DCs Dermis, epidermis IL-12, IL-23, TNF-α, IL-6 
Mature DCs Dermis IL-23 
Plasmacytoid DCs Dermis IFN-α and -β 
TIP-DCs Dermis TNF-α, iNOS 
Langerhans cells Epidermis  
Phagocytes and other related cells 
Macrophages Dermis  
Neutrophils Dermis, epidermis IL-17 
Mast cells Dermis, epidermis IL-17 
Lymphocytes   
Th17 cells Dermis IL-17A and F, IL-21, TNF 
Th1 l cells Dermis IFN-γ 
Th22 cells Dermis IL-22 
Cytotoxic T cells 
(Tc17, Tc1, Tc22) 
Dermis IL-17, IFN-γ, IL-22 
γδ T cells  Dermis, epidermis IL-17 
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Located in the major histocompatibility complex (MHC) class I region (6p21.33), 
PSORS1 is the most strongly associated locus for psoriasis predisposition 
(Trembath et al., 1997), especially for early onset psoriasis (Allen et al., 2005). The 
first gene identified in PSORS1, having significant association with psoriasis 
susceptibility, was HLA-C (Bowcock, 2005; Tiilikainen et al., 1980). Depending on 
the population being studied, the allele HLA-Cw6 is found in about 4–16% of 
healthy controls and in 20%-50% of psoriasis cases, (Gourraud et al., 2014). HLA-
C belongs to the MHC class I heavy chain receptors, which are present on almost 
all nucleated cells. They present intracellular peptides (both self and non-self 
peptides) to the immune system, therefore playing a key role in immune 
surveillance. MHCIs are also critical for CD8+ T cell priming and subsequent 
cytolytic targeting of cells, which supports their important role in the 
pathogenesis of psoriasis (Harden et al., 2015b). The penetrance of the MHC-
associated alleles is never 100% in psoriasis, even for monozygotic twins, which 
indicates the requirement of additional environmental or genetic modifiers for the 
development of specific T-cell receptor arrangements (Bowcock, 2005). However, 
the likelihood of HLA-Cw6 driving the association of PSORS1 has been 
controversial, plausibly due to the extensive linkage disequilibrium (LD) within 
the region. The region also includes the genes CCHCR1 (alpha-helix coiled-coil 
rod homolog) and CDSN (corneodesmosin), both of which have been associated 
with psoriasis susceptibility as well (Asumalahti et al., 2000; Asumalahti et al., 
2002; Tazi Ahnini et al., 1999).  
Interestingly, PSORS1 has been suggested to have an epistatic interaction with 
PSORS4 locus on chromosome 1q21, which contains the epidermal differentiation 
complex (EDC) (Capon et al., 1999a; Capon et al., 1999b). The region harbors genes 
that are essential for the differentiation of keratinocytes and are divided into three 
families: cornified envelope precursor proteins (loricrin (LOR), involucrin (IVL), 
small proline-rich proteins (SPRPs), and late cornified envelope proteins (LCE)), 
keratin filament-binding proteins (filaggrins (FLs), trichohyalin (TCHH), repetin 
(RPTN), hornerin (HRNR), and cornulin (CRNN)), and S100 calcium-binding 
proteins (some of which also act as chemokines and are upregulated during skin 
inflammation) (Chen et al., 2009; Zhao and Elder, 1997). 
 
 
26 
 
 
Figure 3 Chromosomal locations of the PSORS loci. The numbers represent the 
chromosomes. The identified loci are illustrated in grey. Information of the loci are 
collected from Bowcock and Cookson, 2004 and Online Mendelian Inheritance in Man 
(OMIM). 
2.2.1. Psoriasis candidate gene CCHCR1 
The gene CCHCR1 (Coiled-Coil α-Helical Rod protein 1) is located in PSORS1 
(Asumalahti et al., 2000; Asumalahti et al., 2002). The gene has at least two 
transcription start sites (TSSs) (Figure 4) and encodes for several transcripts and 
at least 3 different protein isoforms. The transcripts for the isoforms 1 and 2 are 
transcribed from the second TSS (exon 1b), whereas the transcript starting from 
the first TSS can encode only for the isoform 3, which has therefore a shorter N-
terminus. The protein encoded by the gene, CCHCR1, is predicted to have α-
helical coiled-coil rod domains and possibly a leucine zipper motif, but it exhibits 
little homology with other known proteins; the strongest homologies are with 
various myosins (Asumalahti et al., 2000). Noteworthily, it was originally 
identified that the CCHCR1 gene shares also some structural homology to 
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trichohyalin (TCHH); a gene located at the PSORS4 locus and encoding for an 
intermediate filament-associated protein that is mainly expressed in the granular 
layer of the epidermis (Guillaudeux et al., 1998). 
2.2.1.1. Genetic associations with psoriasis and other diseases 
The location at the chromosomal region showing the strongest associations in 
genome-wide association studies (Zhang et al., 2009), suggests CCHCR1 as a 
plausible psoriasis susceptibility gene in addition to HLA-C. Its role and function 
 
Figure 4 Structure of the CCHCR1 gene. The gene contains 18 exons (not in scale), with 
alternating first exon and transcription start sites (TSS, exons 1a and 1b). The exon 1b 
contains a codon ATG and is able to encode for CCHCR1 isoforms 1 and 2 that are longer 
by their N-terminus than isoform 3, which is translated from ATG in exon 2. The stars show 
the positions of the *WWCC risk haplotype SNPs in exons 4, 14, and 18. 
in the pathogenesis of psoriasis, however, is still unclear. CCHCR1 is highly 
polymorphic and previous studies have identified an allele, CCHCR1*WWCC, 
which is associated with psoriasis susceptibility in several populations 
(Asumalahti et al., 2000; Asumalahti et al., 2002; Chang et al., 2006). The allele 
*WWCC is composed of four nonsynonymous SNPs along the coding region of 
CCHCR1 (Figure 4). In the non-risk haplotype these SNPs encode for amino acids: 
R (rs130065), R (rs130076), G (rs130079), and S (rs1576), whereas in the risk 
haplotype they are W, W, C, and C. The SNPs rs130065, rs130076, and rs1576 have 
been associated primarily with early onset psoriasis (type I) (Allen et al., 2005; 
Chang et al., 2005; Chang et al., 2004; Prieto-Perez et al., 2015). SNPs within 
CCHCR1 have been associated also with nevirapine-induced rash in HIV-infected 
patients, multiple sclerosis, and type 1 diabetes susceptibility (Chantarangsu et 
al., 2011; Cheung et al., 2011; Lin et al., 2015).  
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2.2.1.2. Function 
The function of CCHCR1 has not been extensively studied but the protein has 
been suggested to localize in the cytoplasm, nucleus, and mitochondria and to 
regulate various cellular functions, including steroidogenesis, proliferation, and 
differentiation (Corbi et al., 2005; Sugawara et al., 2003; Suomela et al., 2003; Tiala 
et al., 2007). In addition, a recent study localized the protein CCHCR1 to the P-
bodies, which are sites for mRNA metabolism (Ling et al., 2014). The predicted 
structure of the CCHCR1 protein with risk allele *WWCC differs from the wild-
type by a shorter first alpha-helical domain, which possibly affects the properties 
of the protein.  
CCHCR1 interacts with steroidogenic activator protein StAR, via which it 
regulates the synthesis of steroids from cholesterol in mitochondria (Sugawara et 
al., 2003; Tiala et al., 2007). Moreover, the gene expression for lipid biosynthesis 
has been shown to be decreased, already in the non-lesional psoriatic skin, which 
supports the role of altered lipid metabolism in the pathogenesis of psoriasis 
(Gudjonsson et al., 2009). CCHCR1 has been shown to interact also with RNA 
polymerase II subunit 3 (RPB3), for which it functions as a cytoplasmic docking 
site, thereby controlling myogenic differentiation. (Corbi et al., 2005). In addition, 
it has been shown to interact with enhancer of mRNA-decapping protein 4 
(EDC4), in the P-bodies (Ling et al., 2014). Several other possible interacting 
partners for CCHCR1 have been identified by yeast two-hybrid experiments, 
including: protein kinase C gamma (PRKCG), TNF receptor-associated factor 4 
(TRAF4), DNA polymerase delta subunit 2 (POLD2), inhibitor of nuclear factor 
kappa-B kinase subunit gamma (IKBKG), transforming acidic coiled-coil-
containing protein 3 (TACC3), and with proteins from several viruses and 
bacteria, such as Epstein-Barr virus (EBV), human papillomavirus (HPV), and 
hepatitis C virus (HCV) (Gomez-Baldo et al., 2010; Lim et al., 2006; Ling et al., 
2014; Wang et al., 2011; Xu et al., 2002).  
The expression of CCHCR1 in psoriatic lesions differs from healthy skin or other 
hyperproliferative skin disorders (Suomela et al., 2003; Tiala et al., 2007). CCHCR1 
is expressed in the keratinocytes at the basal layer of the epidermis, in healthy 
skin. In psoriatic lesions, however, CCHCR1 is expressed also in the suprabasal 
keratinocytes above the tip of the dermal papillae, while the hyperproliferation 
marker Ki67 is expressed in the rete ridges, where the expression of CCHCR1 is 
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less prominent (Asumalahti et al., 2002; Suomela et al., 2003). In other 
hyperproliferative inflammatory skin disorders, such as chronic eczema, chronic 
skin ulcers, and lichenoid chronic dermatitis, the expression pattern is absent and 
the expression resembles normal skin. The overexpression of CCHCR1 has been 
shown to affect keratinocyte proliferation in transgenic mice, in which the most 
evident effect occurred after wounding or treatment with 12-O-tetradecanoyl-13-
acetate (TPA). The wound healing was delayed and TPA-induced epidermal 
hyperproliferation was less pronounced in mice with the overexpression of the 
CCHCR1*WWCC risk allele (Tiala et al., 2008). Moreover, the overexpression of 
CCHCR1 had an effect on the expression of several genes relevant in psoriasis 
pathogenesis, these including keratins 6, 16, and, 17 (Krt6/16/17), and genes of the 
epidermal differentiation complex region on the PSORS4 locus (1q21), such as 
S100 calcium binding protein A1 (S100A) and small proline-rich protein (Sprr) 
(Elomaa et al., 2004). 
CCHCR1 is expressed also in different cancers of epidermal origin, such as 
adenocarcinoma of the lung and breast (Suomela et al., 2003). The 
hyperproliferation marker Ki67 was not expressed by the same cells, as in the case 
of psoriasis. The expression of CCHCR1 has been studied also in non-melanoma 
skin cancers: squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) 
(Suomela et al., 2009). It was expressed especially in Ki67 positive proliferating 
cells of the tumors. Furthermore, when compared with normal cultured 
keratinocytes the mRNA expression was upregulated in SCC cultures. Similar 
increase in CCHCR1 expression has been detected in neoplastic cervical high-
grade squamous intraepithelial lesions (Pacholska-Bogalska et al., 2012). 
Moreover, the strongest CCHCR1 expression in SCCs and BCCs was detected in 
areas positive for epidermal growth factor receptor (EGFR). EGFR and related 
receptors are well known markers in several solid tumors and their expression 
and signaling are implicated in pathogenesis of psoriasis as well; especially, many 
of the EGFR ligands are overexpressed in psoriatic epidermis (Schneider et al., 
2008; Yoshida et al., 2008a). The constant stimulation of EGFR is suggested to 
constitutively activate the signal transducer and activator of transcription signal 
protein 3 (STAT3), resulting in effects on skin via alteration of biological processes 
in keratinocytes, such as proliferation, differentiation, and apoptosis (Chan et al., 
2008; David et al., 1996; Sano et al., 2008). In addition, epidermal growth factor 
(EGF) induces CCHCR1 expression in keratinocytes (Tiala et al., 2007), whereas 
interferon-γ (IFN-γ) does the opposite (Suomela et al., 2003). 
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2.3. Transcriptomis 
Several gene expression studies have been conducted on psoriatic skin, providing 
evidence on the transcriptional changes in the lesions but also already in the non-
lesional skin of a patient with psoriasis. Gene expression studies that have 
compared the expression in psoriatic lesional skin with control and/or non-
lesional skin by microarrays have revealed numerous differentially expressed 
genes (DEGs) (Bowcock et al., 2001; Gudjonsson et al., 2010a; Gudjonsson et al., 
2009; Mitsui et al., 2012; Reischl et al., 2007; Suarez-Farinas et al., 2010; Tian et al., 
2012; Yao et al., 2008; Zaba et al., 2009; Zhou et al., 2003). RNA sequencing (RNA-
seq) has provided a new and more specific alternative to microarrays. However, 
only a few RNA-seq studies on gene expression in psoriatic skin have been 
published thus far (Jabbari et al., 2012; Li et al., 2014) and a couple that are limited 
to the microRNA and long non-coding RNA transcriptomes (Gupta et al., 2016; 
Joyce et al., 2011). Most of the previous psoriasis transcriptome analyses have 
used full-thickness skin samples but one study focused on microdissected 
samples that separated the epidermis and dermis (Mitsui et al., 2012).  
Keratinocytes change their gene expression profiles during the development of a 
lesion, due to the stimuli by inflammatory factors. Also the invading 
inflammatory cells affect the gene expression profile of the psoriatic epidermis. 
Most of the inflammatory cells, however, reside in the dermis. Meta-analysis 
derived (MAD) analysis (Tian et al., 2012) that combined 5 different microarray 
data sets of full-thickness samples, comparing lesional skin expression with non-
lesional skin, highlighted atherosclerosis signaling, lipid metabolism, and 
cardiovascular development, strengthening the similarity of the disease with 
other comorbid diseases, such as metabolic syndrome and cardiovascular disease. 
The separate microarray analysis of epidermal and dermal sections of psoriatic 
skin, in comparison with non-lesional skin samples, revealed local production of 
C-C motif chemokine ligand 19 (CCL19) and its receptor CCR7 in psoriatic dermal 
lymphoid aggregates (Mitsui et al., 2012). The study also illustrated the presence 
of mature DC markers LAMP3/DC-LAMP and CD83 in the aggregates, proposing 
lymphoid organization via CCL19/CCR7 in lesional psoriatic dermis.  
The RNA-seq analysis conducted with full-thickness samples of psoriatic lesions 
and heathy controls revealed marked differences in sensitivity, when compared 
with analysis by microarray.  Transcripts identified only by RNA-seq had much 
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lower expression than those also identified by microarray (Li et al., 2014). It is 
commonly observed that the DEGs differ greatly across experiments, partially 
due to variations introduced in the microarray or RNA-seq experimental 
pipelines. RNA-seq increased the detection of differentially expressed transcripts 
(DETs) enriched in immune system processes. Weighted gene co-expression 
network analysis with the shared genes from microarray and RNA-seq 
highlighted epidermal differentiation genes, lymphoid and/or myeloid signature 
transcripts, and genes induced by IL-17 in keratinocytes in this analysis. The 
analysis also emphasized the significant down-regulation of dermally expressed 
genes in psoriatic biopsies, which was suggested to result from technical artefact 
caused by the expansion of the epidermal compartment, emphasizing the 
influence of tissue architecture in expression analyses. 
3. RNA sequencing 
RNA-seq has become a widely used method for transcriptome studies. It uses 
deep-sequencing technologies that provide a far more precise measurement of the 
levels of transcripts and their isoforms than other methods (Wang et al., 2009). 
When compared with microarrays, the main advantages of RNA-seq are: 
sensitivity, ability to detect splice variants, transcription start sites (TSS), and 
intergenic transcripts. 
The transcriptome is the whole pool of transcripts in a cell or a tissue and it varies 
between different tissues or cell types and specific developmental stages or 
physiological conditions. Understanding the transcriptome is essential for 
interpreting the functional elements of the genome and revealing the molecular 
constituents and pathways of cells and tissues. It is also important for 
understanding the pathogenesis of a disease. The key aims of transcriptomic 
studies are: to decipher the expression profile of all species of transcripts, 
including mRNAs, non-coding RNAs, and small RNAs; to determine the 
transcriptional structure of genes and the genome, in terms of their start sites, 5' 
and 3' ends, splicing patterns, and other post-transcriptional modifications; and 
to quantify the changes in expression levels of each transcript during 
development and under different conditions. 
Different RNA-seq methods have different advantages (Hrdlickova et al., 2016). 
In this thesis we have used a highly multiplexed and strand-specific method that 
was originally designed for single-cell RNA 5’ end sequencing (single-cell tagged 
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reverse transcription, STRT; Figure 5) (Islam et al., 2012). Since the epidermis of 
the skin is very thin, the amount of RNA extracted is also very modest. Therefore, 
this method, which is designed for minute amounts of RNA, is very suitable for 
our samples. In addition, the early bar-coding strategy reduces costs and time. 
Compared with previous methods, this one is unsuitable for the detection of 
alternatively spliced transcripts but is more suitable for large-scale quantitative 
analysis, as well as for the characterization of transcription start sites, yielding 
clues for gene regulation. 
3.1. Normalization 
Normalization can be described as the removal of systematic experimental bias 
and technical variation to improve the identification of changes in the transcript 
expressions, across different conditions (Meyer et al., 2010). There are several 
normalization methods published, such as median and quantile normalization 
methods and probably the most well-known is the reads per kilobase of 
transcripts per million mapped reads (RPKM) normalization (Mortazavi et al., 
2008). Another strategy aims to represent the ‘‘global fold-change’’ by introducing 
a scaling factor called trimmed mean of M-values (TMM) (Robinson and Oshlack, 
2010), resulting in samples of similar total expression, which may not be 
biologically correct. All of the methods mentioned above, depend on the global 
gene expression. The method used in the RNA sequencing performed in this 
thesis, applies normalization by RNA spike-in (Katayama et al. 2012, Islam et al., 
2011, Islam et al. 2012). 
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Figure 5 Schematic overview of the STRT RNA sequencing method with RNA spike-in 
normalization. The tissues/cells are lysed, RNA spike-in molecules added, and mRNAs 
converted to cDNA. By using a template-switching mechanism; a bar code and an 
upstream primer-binding sequence are introduced simultaneously with reverse 
transcription. All the cDNAs are pooled and prepared for sequencing - preparation 
including: fragmentation, adapter ligation, and PCR amplification. SOLEXA refers to the 
sequencing instrument used originally; presently, the most commonly used platform is 
Illumina. Remade and modified from Islam et al., 2012. 
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AIMS OF THE STUDY 
The main aim of this study was to identify the causative elements behind psoriasis. 
Thus, the thesis is focused on identification of aberrant signaling pathways in 
psoriatic epidermis and studies with psoriasis candidate gene CCHCR1.  
The aim of the first RNA-seq study was to improve RNA-seq methods with which 
to investigate samples with varying amounts of poly A+ RNA and to identify 
transcriptional differences between different keratinocyte sample types: tissue 
samples, cultured keratinocytes, and keratinocyte cell line. The improved method 
was applied to the psoriasis study, where the aim was to focus on differences in 
transcriptome profiles of healthy control, non-lesional psoriatic epidermis, and 
lesional psoriatic epidermis. A database survey (NCBI's GenBank) suggested that 
CCHCR1 has alternative transcripts 1, 2, and 3, at least, of which 1 is the longest 
and 3 the shortest. We were interested in the effects of CCHCR1 on transcriptional 
regulation, as many of its already known functions implicate a role in 
transcriptional regulation. Here we focused on the effects of the CCHCR1 protein 
isoforms encoded by the longest and shortes transcripts.  
The specific aims of this thesis were to: 
1. Identify transcriptome and gene expression profiles of psoriatic 
healthy/lesional vs control skin (I, II, Figure 6). 
2. Investigate the isoform/haplotype specific function of CCHCR1 (III), its 
effects on transcription and signaling pathways, and relevance in 
psoriasis (IV) (Figure 7) 
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Figure 6 RNA-seq: keratinocyte and psoriasis study samples. The top row represents the 
psoriasis samples and the blue arrows indicate which samples were compared together. 
The orange arrows indicate the comparisons in the keratinocyte study. The control samples 
were used in both of the studies. SG = skin graft. 
 
Figure 7 RNA sequencing: CCHCR1 cell lines. CCHCR1 RNA-seq study compared the 
transcriptomes of the different cell lines overexpressing CCHCR1 with the wild type and 
vector control cell lines.  
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MATERIALS AND METHODS 
1. Patient material 
1.1. Blood samples (III) 
We utilized DNA samples from Finnish and Swedish psoriasis families for the 
association analysis (Inerot et al., 2005; Kainu et al., 2009; Suomela et al., 2007). 
Thus, we used family trios to investigate association of genetic markers of interest 
by measuring their transmission from parent to offspring. The Swedish blood 
samples were collected with the help of the Swedish Psoriasis Association and 
approved by the Regional Ethics Committee, the Finnish samples were approved 
by the Ethics Committees of Helsinki, Turku, Tampere, and Oulu University 
Central Hospitals and Central Hospital of Päijät-Häme. The samples used for the 
association analysis consisted of trios from 508 psoriasis families in total, 
including 245 Finnish and 263 Swedish families. 
1.2. Split-thickness skin grafts and full-thickness biopsies (I, II, III, IV) 
Split-thickness skin grafts (SGs) measuring 5×2 cm were collected with a 
compressed air-driven dermatome with a fixed thickness setting of 4-6/1000 
inches, to obtain a representative sample of epidermis to its full thickness with 
minimal dermis involvement from the donor site skin. Psoriasis patients were 
sampled from both the lesional and non-lesional skin and healthy control skin 
was obtained from reductive mammoplastic or microvascular free flap surgery 
patients. The samples were immediately immersed in RNA stabilization reagent 
(RNAlater) to ensure minimal manipulation and gene expression changes and the 
qualities of the SGs were examined from haematoxylin-eosin-stained paraffin 
sections; too thin samples that were missing a part of the epidermis (e.g. the basal 
layer) were discarded from further analysis and not selected for RNA-seq (e.g. 
sample PN.08). Full-thickness skin samples (3-mm diameter punch biopsies) were 
collected in order to initiate keratinocyte cultures. All participants provided 
written informed consent under a protocol adherent to the Helsinki Guidelines 
and the collection of skin samples was approved by the Ethics Committee of the 
Hospital District of Helsinki and Uusimaa and by the Committee of Skin and 
Allergy Hospital, Helsinki University Central Hospital. 
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2. SNP genotyping and association analysis (III, IV) 
For the association analysis, we genotyped a SNPs rs3130453 (here named as 
CCHCR1*Iso1/3) and rs130076 (CCHCR1*WWCC/RRGS) from DNA extracted 
from the Finnish and Swedish blood samples (III). Genotyping was performed 
with commercial allelic discrimination assays with pre-designed probes and 
primers (TaqMan). Association of the SNPs in focus was investigated with 
transmission disequilibrium test (TDT), by using HaploView for the analysis. We 
also genotyped these SNPs and determined the HLA-Cw*06:02 genotype, also 
with commercial allelic discrimination assays with pre-designed probes and 
primers (TaqMan) (Nikamo and Ståhle, 2012), from DNA extracted from the SGs 
(IV). Sample C.05 was not genotyped due to lack of sample for DNA extraction. 
3. Cell cultures, transfections, and generation of stable cell lines (I, II, 
III, IV) 
Cells cultured in this thesis were: human embryonic kidney (HEK293), human 
immortalized keratinocyte (HaCaT), and fibroblast-like (COS-7) cell lines and 
primary normal human epidermal keratinocytes (NHEK, commercial; KC, 
primary keratinocytes extracted from full thickness samples). 
Plasmid transfections for HEK293, HaCaT, COS-7, and NHEK/KC cells were 
performed with a nonliposome-based transfection reagent (Fugene HD) (II, III). 
Constructs used for the transfections were cloned in vectors containing either no 
tag or pDsRed tag (CCHCR1 transcripts for isoforms 1 and 3 with *WWCC/*RRGS 
haplotypes) or GFP tag (shRNA constructs) (pCMV5, pDsRed-Monomer-N1, and 
pRNAT-CMV3.2/Neo). Stably overexpressing and silenced cell lines were 
generated by transfecting either CCHCR1-pDsRed (Iso1Non-risk, Iso1Risk, 
Iso3Non-risk, and Iso3Risk) or shRNA constructs or vector into HEK293 cells (III). 
We measured the overexpression and selected the cell lines that had the most 
similar fold changes (of these Iso3Non-risk had the strongest overexpression). 
Epidermal keratinocytes (KCs) were isolated from the full thickness skin samples 
with dispase digestion, which was followed by trypsinization (I, II). KCs were 
cultured in keratinocyte growth medium with 0.06 mM calcium on cell culture 
disks coated with collagen I. Samples were collected for RNA-seq from early 
(passage 1; EKC) and late passages (passage 5 or 6; LKC). KCs were also cultured 
for confocal microscopy. 
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The cover slips or cell culture wells were coated with collagen I when transfected, 
used for immunofluorescent stainings, proliferation assay, or treated with 
nocodazole. 
3.1. Cell treatments (III) 
Stably CCHCR1-overexpressing HEK293 cell lines were incubated for 1 h with 
1μM nocodazole at 37°C, for the disruption of the microtubules. Cell cycle was 
synchronized by overnight incubation with 0.3μM nocodazole. Treatment with 
EGF was performed on subconfluent cells that were grown in the presence of 
20ng/ml or 100ng/ml EGF. After 2, 6, or 18 h the cells were lysed for western 
blotting or RNA extraction.  
4. Antibody stainings (II, III, IV) 
All targets for the primary antibodies and stains used in this thesis are listed in 
Table 2. 
4.1. Immunofluorescence microscopy (II, III, IV) 
Cells for the immunofluorescence (IF) studies were grown on cover slips with 
collagen I coating and fixed with methanol or 4% paraformaldehyde-phosphate 
buffered saline solution, depending on the antibody to be used. After 
paraformaldehyde fixation cells were permeabilized with 0.1% Triton-X100 in 
PBS. Indirect immunolabelling was carried out for the following proteins by using 
commercial antibodies (except for CCHCR1 (Asumalahti et al., 2002)): CCHCR1, 
γ-tubulin, β-catenin (CTNNB1), phospho-β-catenin (S33/37/T41) (P-CTNNB1), α-
tubulin, vimentin (VIM), golgi autoantigen, golgin subfamily a 2 (GM130), KRT17, 
pan-cytokeratin, actin, complex IV cytochrome c oxidase subunit II (MTCO2), 
caspase recruitment domain-containing protein 6 (CARD6), EDC4, and 
decapping enzyme 1 A, s. cerevisiae homolog of (DCP1A). The cells were stained 
with appropriate antibodies and the nuclei with 4',6-diamidino-2-phenylindole 
(DAPI) and the pictures were taken with a confocal microscope. 
4.2. Immunohistochemistry (II, III) 
Formalin fixed paraffin sections (5 μm) were stained with a peroxidase-based 
method (ImmPRESS™ Reagent kit) and epitope retrieval was carried out by a 
heat-mediated method in sodium citrate buffer. The following proteins were 
targeted in the immunohistochemistry (IHC) studies via indirect antibody 
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labeling: PYCARD, CARD6, interferon-gamma-inducible protein 16 (IFI16), NLR 
family pyrin domain-containing 10 (NLRP10), and humanin. Normal rabbit IgG 
was used as a negative control. 
Table 2 Targets of primary antibodies and stains used in this thesis 
Antibody Sample  Method Used in 
Actin-phalloidin HEK293 IF III 
CARD6 KC, SG IF, IHC, IEM II 
β-catenin HEK293 IF III 
P-β-catenin  
(S33/37/T41) 
HEK293 IF III 
CCHCR1 HEK293, HaCaT, COS-7, 
NHEK/KC, SG 
IF, IEM, WB III, IV 
DAPI HEK293, HaCaT, NHEK/KC IF II, III, IV 
DCP1A HEK293 IF IV 
EDC4 HEK293 IF IV 
GAPDH HEK293 WB III 
GM130 HEK293 IF III 
Humanin SG IHC II 
IFI16 SG IHC II 
Pan-cytokeratin HEK293 IF, WB III 
KRT17 HEK293 IF, WB III 
MTCO2 KC IF II 
NLRP10 SG IHC II 
PI HEK293 FACS III 
PYCARD (ASC, 
TSM1) 
SG IHC, IEM II 
STAT3 HEK293 WB III 
P-STAT3(Tyr705) HEK293 WB III 
P-STAT3(Ser727) HEK293 WB III 
Ac-
STAT3(Lys685) 
HEK293 WB III 
α-tubulin HEK293 IF, WB III 
β-tubulin HEK293 WB III 
γ-tubulin HEK293, HaCaT, NHEK IF III 
Vimentin HEK293 IF, WB III 
IF, immunofluorescence; IHC, immunohistochemistry; IEM, immunoelectrol 
microscopy; WB, western blot; FACS, fluorescence-activated cell sorting 
4.3. Immunoelectron microscopy (II, III) 
Cultured cells and skin biopsies were fixed with 4% paraformaldehyde-PBS 
solution for the immunoelecton microscopy (IEM) studies. Prior to immersion in 
2.3 M sucrose-PBS solution, the cell culture samples were additionally immersed 
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in 12% gelatin-PBS. The skin biopsies (full-thickness) were frozen in liquid 
nitrogen, from which thin cryosections were cut with a microtome. CCHCR1 was 
targeted for detection by antibodies and protein-A gold conjugate in the cultured 
cells and skin samples. PYCARD and CARD6 were labeled from the skin samples. 
Labeling was detected with a transmission electron microscope. 
4.4. Western blot (II, III) 
Cell for western blot (WB) were grown on 6-well plates and homogenized with 
Laemmli buffer containing 5% β-mercaptoethanol. Western blot analysis was 
carried out by standard SDS-PAGE and immunostaining protocols, by targeting 
the following proteins via indirect antibody labeling: actin, CCHCR1, KRT17, 
pan-cytokeratin, STAT3, P-STAT3(Tyr705), P-STAT3(Ser727), acetyl-
STAT3(Lys685), and VIM. Immunostaining with antibodies against α or β-tubulin 
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used to control 
loading. Signals were detected by enhanced-chemiluminescence (ECL). 
5. RT-PCR, quantitative real-time PCR, and RNA sequencing 
5.1. RNA extraction (I, II, III, IV) 
Total RNA was purified from the cell lines and tissue samples with silica-
membrane based kits (RNeasy Plus Mini or miRNeasy Mini), complemented with 
DNase treatment to avoid DNA contamination. RNA concentrations were 
measured by spectrophotometric and fluorometeric methods and the quality 
controlled by a nanofluidics device (RNA integrity number for all samples >8). 
Total RNA was reverse transcribed to cDNA using random hexamer primers.  
5.2. Reverse transcription PCR (III) 
The expression of CCHCR1 transcript variants 1 and 3 was analyzed in different 
tissues and cell lines by standard reverse transcription PCR (RT-PCR). The 
expressions were studied using variant-specific primers in commercial human 
multiple tissue cDNA and fetal and tumor sample panels, HaCaT and HEK293 
cell lines, and NHEK. GAPDH expression was used as a control.  
5.3. Quantitative real-time PCR (I, II, III, IV) 
Quantitative real-time PCR (qPCR) was applied to measure the expression of 
target genes in the cell line or tissue samples. We used both commercial pre-
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designed primers and probes (TaqMan) or designed specific primers and detected 
the amplification with a DNA stain-based method (SYBR green). Targets 
quantified were I) Ribosomal phosphoprotein genes RPLP13A and RPLP0 and 
GAPDH (equal amount of the spike-in RNA mix was added to each cDNA 
synthesis reaction to control for the PCR reaction), II) CARD6, IFI16, IL8, 
PYCARD, RPLP13, and GAPDH, III) CCHCR1, KRT17, TATA-binding protein 
(TBP), and GAPDH, and IV) synaptotagmin 1 (SYT1), IL8, amphiregulin (AREG), 
talin 1 (TLN1), fibronectin 1 (FN1), protein phosphatase 2 (PPP2CA), and 
hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1).  
5.4. RNA sequencing (I, II, III, IV) 
Qualified total RNA samples were used for RNA-seq library preparation 
according to the STRT protocol, which was adjusted for 10 ng samples. The 
libraries, of 3 technical replicates, were sequenced using an ultra-high-throughput 
sequencing system (Illumina). Preprocessing of the reads, alignments, and per-
gene quantitations were analysed using an established pipeline (Islam et al., 2012). 
The 5’-end regions of the assembled transcripts were merged as Transcript Far 5’-
ends (TFEs), which were annotated with UCSC genes (II, III). Reads aligned 
within the TFEs were counted by samples again, and normalized using the eight 
synthetic spike-in RNAs of known concentration that were added to each sample. 
SAMstrt (Katayama et al., 2013) and SAMseq (Li and Tibshirani, 2013) packages 
were used for the differential expression analysis. Differentially expressed genes 
or transcripts were extracted by multiclass response test; threshold of significance 
was Local-FDR < 1% (I) or 5% (II, IV).  
6. Cell proliferation and morphology (III) 
The morphology of the cells was observed from the confocal microscopy images 
and the size of the DAPI stained nuclei in the stable cell lines measured from the 
images. The cell proliferation of stably overexpressing CCHCR1 cell lines was 
determined with an automated cell counter. Cells were seeded on 12-well plates 
and after 24 and 48 h of incubation they were trypsinized and counted. We also 
utilized DNA-binding dye-based cell proliferation assay (CyQuant) to study cell 
proliferation. Briefly, the cells were seeded on 96-well plates and allowed to grow 
for 0–48 h. The cells were frozen at specific timepoints and stained; the 
fluorescence was measured with a label reader. We used flow cytometry to study 
cell cycle in the CCHCR1 cell lines. We synchronized the cells with nocodazole 
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into G2/M-phase, to determine cell cycle progression of the synchronized cells. 
The cells were collected at three time points (0, 5, and 10h) and fixed with ice cold 
70% ethanol. After RNA depletion with ribonuclease A, the nuclei were stained 
with propidium iodide (PI).  
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RESULTS 
1. RNA sequencing (I, II, IV) 
We collected split-thickness skin graft (SG) biopsies, with minimized inclusion of 
dermis, from nine control (C), five psoriatic non-lesional (PN), and six lesional 
(PL) donors and extracted total RNA (Figure 6). Full-thickness skin biopsies were 
collected from the control donors for keratinocyte (KC) cultures from which total 
RNA was isolated at early (1st; EKC) and late (5th-6th; LKC) passages. HaCaT 
cells were cultured and RNA extracted from them as well (I, IV, Figure 7). These 
samples were used for two separate studies: keratinocyte study (C/SG, EKC, LKC, 
and HaCaT) and psoriasis study (C, PN, and PL). Thus, the data from the control 
(C) samples were used in two different studies and publications.  
We also extracted RNA from the CCHCR1 overexpressing cell lines (WT, V, Iso1N, 
Iso1R, Iso3N, and Iso3R), which were used in the CCHCR1 study (Figure 7). The 
study also included CCHCR1 knock down cell lines. The extracted RNA samples 
were subjected to 5’-end RNA-seq. (IV) 
1.1. Varying polyA+ RNA content in different samples (I) 
When comparing the expression profiles of samples, a common assumption is 
that the individual cells contain equal amounts of RNA. Different tissue or cell 
types, however, might not have equal amounts of RNA per cell. Therefore, we 
compared the differences in polyA+ RNA contents in our samples. We employed 
a recently developed method for normalization, SAMstrt (Katayama et al., 2013), 
which utilizes spike-in RNAs. The estimated polyA+ RNA contents, which were 
quantified against the added spike-in RNA controls, varied in different sample 
types (I). This can lead to the misinterpretation of differential expression when 
traditional endogenous gene-based normalization is applied. Validation by qRT-
PCR confirmed the spike-in RNA normalization-based upregulation of two 
housekeeping genes RPLP0 and RPL13A, both of which were predicted to remain 
unchanged or downregulated by the gene-based normalization. In conclusion, the 
use of spike-in-based normalization produced consistent results with qPCR 
validations, whereas the traditional gene-based normalization method led to 
inaccurate expression profiles. 
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2. Characterization of the keratinocyte study samples (I) 
We assessed the transcriptome profiles of the healthy skin SGs, KCs (early and 
late), and HaCaT cells. Hierarchical clustering confirmed significant dissimilarity 
between the three sample types and we found 11,908 DEGs altogether. The STRT 
RNA-seq method with synthetic RNA spike-in normalization reflected the 
activity of the cell type and revealed variation of polyA+ RNA content per total 
RNA in the different sample types. We used principal component analysis (PCA) 
(Figure   8a) to elucidate dissimilarity between the samples, and the principal 
components with gene set enrichment analysis (PC-GSEA) to find the associations 
between genes and phenotypes. The principal components (PCs) revealed 
divergence in differentiation and mitochondrial phenotypes between SGs and 
cultured cells, G1/S-transition between HaCaTs and EKCs, and senescence and 
cellular aging responses between HaCaTs and LKCs. The tissue samples differed 
from the cultured cells, as expected, and the HaCaT cell line differed remarkably 
from the other cultured cells, as shown by PCA and by their cytokeratin profiles. 
 
Figure 8 Principal component analysis classification of the samples used in the 
keratinocyte and psoriasis studies. a) PC1 demonstrates the difference between SGs and 
other sample types, whereas PC3 separates HaCaTs from KCs and SGs. Symbols in SGs 
and KCs illustrate identical donors in three technical replicas each. SG, Split-thickness skin 
graft; EKC, early passage keratinocyte; LKC, late passage keratinocyte. b) PC1 illustrates 
the clustering of healthy control (C), psoriasis non-lesional (PN) and lesional (PL) samples. 
Percentages beside of the axis labels are the contribution ratios. Modified from I and II.  
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3. Characterization of the psoriasis study samples (II) 
In the psoriasis study we investigated the clustering of SG samples by PCA 
(Figure 8b), which revealed clustering of the three different sample groups but 
significant overlap of the non-lesional and healthy control skin samples (PN and 
C) and separation from the lesional samples. Some non-lesional samples clustered 
between the control and lesional samples, suggesting transcriptional alterations 
already in the non-lesional skin.  
We performed group-wise (GW) comparisons between the three sample groups 
at first. The comparison of lesional sample group with the control (PLvsC) or non-
lesion (PLvsPN) groups revealed 2436 and 3541 upregulated and 2550 and 494 
downregulated transcripts, respectively (Fold Change (FC) >1.5 and <0.75, False 
Discovery Rate (FDR) <0.05). According to positional analysis: the upregulated 
transcripts showed enrichment from PSORS4 locus. The GW comparison of non-
lesion with control skin (PNvsC) identified 35 DETs; 28 of which were 
upregulated and 7 downregulated. Interestingly, 12 of the transcripts mapped to 
the known PSORS loci; PSORS4 was the most represented among the upregulated 
transcripts, as shown also in previous studies (Gudjonsson et al., 2009). Of the 
differentially expressed transcripts, we selected the classes that represented 
annotated genes and identified 2720 (PLvsC), 2610 (PLvsPN), and 25 (PNvsC) 
DEGs. We also compared the expressions pair-wisely between lesional and non-
lesional skin from each psoriatic patient separately (data not shown) to see if the 
different approach in analysis would alter the results from pathways analysis or 
if the medications had significant effects. We analyzed the DEGs that were shared 
in all patients and got similar results as from the GW analysis. 
4. Expression profiling (II) 
4.1. Psoriasis non-lesional skin 
The comparison of the two healthy skin sample groups, psoriasis non-lesional 
with the control samples, revealed upregulation of genes for keratinocyte and 
epidermal differentiation and defense response already in the non-lesional 
samples. Most of the upregulated transcripts were induced also in the lesions 
(PLvsC) and highlighted the EDC region (S100A7, S100A12, SPRR2A, SPRR2B, 
SPRR2D, SPRR2G, and LCE3E). There were two unique transcripts, however; 
contactin-associated protein-like 3 (CNTNAP3B) and the mitochondrial 
transcripts (ChrM) named in the alignment step as TVAS5, both of which have 
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not been implicated in psoriasis before. The most frequent mitochondrial reads 
mapped at the start site of mitochondrially encoded 16S ribosomal RNA 
(MTRNR2 gene) that encodes for a polypeptide called humanin.  
Among the downregulated transcripts in the non-lesional samples we identified 
only three DEGs one of which, interestingly, was the nuclear gene homolog of 
MTRNR2: MTRNR2L1 (humanin-like). Due to the high similarity in sequence 
among humanin-like genes (Bodzioch 2009), the specific quantitation of humanin 
and its nuclear homologs was challenging. We demonstrated that humanin and 
humanin-like proteins are strongly expressed in keratinocytes but were unable to 
detect any difference between the three sample types. As the RNA-seq data 
exhibited disturbed gene expression in the non-lesional skin, it remains to be 
studied whether humanin and its homologs play a role in the pathogenesis of 
psoriasis. 
4.2. Psoriasis lesional skin 
We investigated the DEGs from the PLvsPN and PLvsC comparisons (group-wise, 
GW) with pathway and functional analysis and got similar results from both of 
the comparisons; thus, many similar pathways and functions were highlighted in 
both comparisons. Therefore, we analyzed the DEGs that are shared in the two 
comparisons. Functional annotation analysis highlighted enrichment of the 
upregulated genes in epidermal differentiation-related gene ontology (GO) 
groups that included the EDC region encoded genes (LCE and SPRR). Defense 
response, oxidoreductase, protease, and lipid degradation were among the most 
significant functional clusters as well. Caspase recruitment domain (CARD) and 
caspase gene families were highlighted in the analyses. Pathway analyses 
identified enrichment in e.g. lysosome, NOD-like receptor (NLR), and RIG-I-like 
receptor (RLR) signaling pathways. Missing from the most significant and largest 
groups in the GW-PLvsC comparison; the analysis of the upregulated genes from 
the GW-PLvsPN comparison highlighted GOs related to mitochondria and 
oxidative phosphorylation, showing enrichment also in the pair-wise comparison. 
The absence might, however, result from the heterogeneity of the patients. 
We focused next on the NLR signaling pathway, which was highlighted as a 
upregulated pathway in the lesional samples. RLR signaling and cytosolic DNA 
sensing pathways rose up as well and all three pathways shared several genes. 
The NLR signaling pathway included several highly upregulated transcripts: 
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nucleotide-binding oligomerization domain protein 2 (NOD2), CARD6, CARD18, 
CASP5, IL1B, IL8, and chemokine CXCL1 (GW-PLvsPN, FC >1 x 108). Also several 
other NLR signaling-related components, with less upregulation, were 
identifiable: NLRP10, NLR family member X1 (NLRX1), CASP1, CASP8, and 
PYCARD (ASC). The receptors of the cytosolic DNA sensing and RLR signaling 
pathways; DNA-binding receptor genes AIM2 and IFI16 and RNA helicase 
protein genes IFIH1 and DDX58 (RIG-I), were also upregulated. Several other 
RLR-related transcripts were upregulated as well, including ubiquitin-like 
modifier ISG15 and CYLD.  
We verified the upregulation of CARD6, IFI16, PYCARD, and IL8 in lesional skin 
samples by qPCR. In addition, we selected a few proteins, encoded by the DEGs 
NOD2, PYCARD, IFI16, CARD6, and NLRP10, whose expression pattern has not 
been thoroughly studied in psoriatic skin before, or it has remained unclear. We 
used immunohistochemistry to examine and verify the expression and 
localization of the proteins. Immunohistochemistry demonstrated that NOD2 
expression, indeed, was induced in the lesional epidermis, including 
keratinocytes. The expression varied between individuals in psoriasis non-
lesional and lesional skin and in the non-lesional samples, especially, there was 
more variation from weak to increased expression. On the cellular level, NOD2 
was localized in the cytoplasm and in some cells on the cell membrane. PYCARD 
expression in the epidermis was observed in all sample groups. The expression 
level and pattern, however, differed in the lesions, where the expression was 
strongly induced in the cytoplasm, and in some cells in the nucleus. The overall 
PYCARD staining in the non-lesional samples was weaker and some samples 
showed nuclear staining. The control skin exhibited only a few PYCARD positive 
nuclei, and its overall staining was weaker than in the psoriasis patients. The 
cytoplasmic PYCARD induction in the lesional samples was observable also in 
IEM. Interestingly, in some keratinocytes the PYCARD labeling formed clusters 
(diameter around 500 nm) that localized with cytoplasmic membrane structures, 
possibly small vesicles. IFI16 staining was localized into cell nuclei in the psoriasis 
samples and strongly upregulated especially in the lesional epidermis. Controls 
had only a few IFI16 positive nuclei and in some samples we detected weak 
cytoplasmic expression, which was absent from the psoriatic SGs.  
CARD6 protein was detectable as granular cytoplasmic staining and also in nuclei. 
We identified the granular staining as mitochondria, by colocalizing with 
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mitochondrial marker MTCO2. The localization was verified also by IEM, in 
which the CARD6 was observed at the cell-cell contacts as well. Some of the non-
lesional samples showed induced expression as well but the control skins were 
almost CARD6 negative. NLRP10 staining was observable all over the epidermis 
but of the selected NLR signaling pathway proteins, it remained as the only one 
for which we couldn’t detect any difference between psoriatics and controls. 
The shared genes of the GW-PLvsPN and -PLvsC comparisons contained 220 
downregulated genes that were enriched in such functions as: extracellular matrix, 
blood vessel development, and cell junction. Pathway analysis recognized, e.g., 
pathways in cancer, cytokine-cytokine receptor interaction, and focal adhesion. 
The comparison PLvsC recognized several DEGs that were absent from the 
PLvsPN comparison; the separate analysis therefore revealed pathways that were 
unidentified in the PLvsPN comparison, such as Wnt, TGF-β, and Notch signaling. 
5. RNA-seq of skin graft samples refined previous findings in 
psoriasis (II) 
We wanted to estimate the advantages of the methods used in this study design 
by comparing our RNA-seq data of SG samples with: two large microarray 
studies of full-thickness samples by Gudjonsson et al. and Tian et al. (Gudjonsson 
et al., 2009; Tian et al., 2012) and one with microdissected epidermis and dermis 
by Mitsui et al. (Mitsui et al., 2012) and with a RNA-seq study of full-thickness 
samples by Li et al. (Li et al., 2014). The comparison with two microarray studies 
done on full-thickness samples of psoriatic lesional and non-lesional skin resulted 
in the detection of 2232 DEGs that were unique only in our study. The RNA-seq 
of psoriatic full-thickness lesional and control skin differed from our study in 
several ways but similar functional categories and pathways were identifiable in 
both studies. The studies shared 1566 DEGs but numerous unique transcripts as 
well; 1200 and 7515 DEGs in the SG or full-thickness skin, respectively. Genes that 
were unique for our SG samples were enriched in such categories as Wnt 
signaling, ubiquitin proteasome pathway, lysosome, and focal adhesion. The NLR 
signaling pathway included DEGs, in our SG samples, which were not recognized 
from the full-thickness samples (e.g. CASP1, CASP8, CARD18, CYLD, and 
TNFAIP3).  DEGs enriched in lymphocyte (upregulated), muscle, or secretion 
(downregulated) were recognized in the full thickness samples whereas in our 
SGs they were missing or not among the significantly altered ones. 
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The microdissected epidermis and dermis samples were from lesional and non-
lesional psoriatic skin. When we compared their DEGs with our data, 517 were 
shared and 2339 unique for our SGs and 679 for the microdissected epidermis. We 
identified, for example, several LCE, SPRR, and KRT genes that were undetectable 
in the microarray. Among NLR signaling; genes such as NOD2, PYCARD, DDX58, 
CASP1, and IL8 were recognized in both studies but transcripts for CARD6, 
CARD18, CASP8, IL1B, and pyrin domain-containing protein 1 (PYDC1) were 
upregulated only in our study. Only 3% of the DEGs from our study were 
detectable in the microdissected dermis data. To validate whether the variation 
on the amount of dermis between the skin samples has an effect on our RNA-seq 
results, we compared the expression of fibroblast specific genes, COL3A1 and 
COL1A2, in three sample groups. Some of the samples exhibited a slight decrease 
in the expression of these markers, suggesting that the architecture and thickening 
of the epidermis in lesional samples can create some downregulation of the 
dermal components. When compared with the non-lesional samples; the relative 
decrease of the dermis in the lesional samples is more pronounced in SGs than in 
full-thickness samples. The number of downregulated genes in the lesional SG 
samples, however, is lower than the number observed in the full-thickness studies. 
6. Functional characterization of the psoriasis candidate gene CCHCR1 
6.1. Association of a SNP within CCHCR1, with psoriasis (III, IV) 
We genotyped the SNP rs3130453 (G/A) in 508 Finnish and Swedish psoriasis 
families (III). The A allele, that encodes for a stop codon, thus enabling the 
translation of only CCHCR1 isoform 3 (named here as *Iso3 allele), showed 
preferential transmission from heterozygous parents to affected offspring (P<10−7). 
We also genotyped, from the same family material, the SNP rs130076 (C/T) from 
in the CCHCR1*WWCC (“Risk”) haplotype. The risk allele (T) showed association 
with psoriasis (P<10−13), as expected. We extended, therefore, the risk allele as 
CCHCR1*Iso3WWCC for the haplotype analysis showed the transmission of 
*Iso3Risk (P<10−16) to affected offspring. We also analyzed these SNPs from the SG 
samples (IV). There were thus eight controls and seven psoriasis samples. Five of 
the psoriatic samples were homozygous for the CCHCR1*Iso3 allele, whereas only 
two out of eight were homozygous in the controls. None of the psoriatic samples 
had the homozygous *Iso1 genotype. Five out of seven psoriatic samples were 
heterozygous for the Risk (*WWCC) haplotype whereas five out of eight controls 
had the homozygous Non-risk haplotype. One of the control samples, however, 
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had the homozygous Risk haplotype. We also genotyped the most known 
psoriasis-associated haplotype HLA-Cw*06:02 and found that most of our control 
samples were negative for the haplotype (six out of eight) but most of the psoriasis 
samples were heterozygous positive (five out of seven). 
Table 3 CCHCR1*Iso3WWCC and HLA-Cw*06:02 genotypes of the SG samples 
Sample CCHCR1*Iso3 CCHCR1*WWCC HLA-Cw*06:02 
C.02 NP NP NN 
C.04 NN NN NN 
C.07 NP NN NN 
C.09 PP NP NP 
C.10 NP NN NN 
C.11 NN NN NN 
C.12 PP PP NP 
C.14 NP NN NN 
P.02 PP NP NP 
P.03 NP NP NP 
P.05 PP NP NP 
P.06 PP NP NP 
P.07 PP NP NP 
P.08 PP NN NN 
P.09 NP NN NN 
NN= homozygote (negative), NP= heterozygote, PP= homozygote (positive) 
6.2. Localization of CCHCR1 at the centrosome and P-bodies (III, IV) 
We localized both the endogenous and overexpressed CCHCR1 at the centrosome 
in our studies (III, Figure 9). The endogenous CCHCR1 was investigated in 
HEK293 and HaCaT cell lines and transiently transfected CCHCR1 was studied 
in NHEKs. Most of the functional studies, however, were performed in the stably 
overexpressing HEK293 cell lines, in which both CCHCR1 isoforms, with either 
Risk or Non-risk haplotype, showed overlapping or adjacent expression with the 
centrosomal marker γ-tubulin. In the centrosome, CCHCR1 also colocalized with 
β-catenin and its phosphorylated form. IEM studies with the stable HEK293 cells 
overexpressing isoform 1 revealed that CCHCR1 is present at the pericentrosomal 
region. The overexpressed CCHCR1 was detectable throughout the cell cycle. The 
localization, however, was dynamic and fluctuated especially during mitosis; 
CCHCR1 localized at the midbody near the end of the cytokinesis. (III) 
CCHCR1 was also visible as cytoplasmic granules, the size of which varied 
between the overexpressed isoforms (III). Coiled-coil region-containing proteins 
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form aggregates easily. Likewise CCHCR1, the majority (75%) of centrosomal 
proteins contain coiled-coil regions in their structure (Andersen et al., 2003). We 
noticed, however, that Iso3Risk formed larger granules in the cytoplasm, when 
compared with the other three forms (both in the stable cell lines and with 
transient transfections, in different cell lines). As CCHCR1 Iso3Non-risk was 
recently localized at P-bodies (Ling et al., 2014), we studied if the overexpressed 
CCHCR1 colocalizes with the P-bodies, by immunostaining the P-body markers 
EDC4 and DCP1A (IV). Some of the granules colocalized with the P-bodies, in the 
stable cell lines, but we noticed a difference between the isoforms; in the isoform 
1 -overexpressing cell lines (especially Iso1Non-risk), the P-body markers had 
only seldom colocalization with CCHCR1. In the isoform 3 -overexpressing cell 
lines, however, the P-body staining overlapped almost completely with the 
cytoplasmic granules, including the centrosomal CCHCR1. Immunofluorescent 
staining of vimentin suggested, however, that the centrosomal CCHCR1 was not 
aggresomal accumulation, which is an organelle composed of misfolded 
aggregated proteins, surrounded by a vimentin cage, and located adjacent to the 
centrosome (I) (Johnston et al., 1998). We also excluded the possible localization 
of Iso3Risk CCHCR1 with the cis-golgi, as it surrounds the centrosome and the 
showed strong perinuclear staining, especially in transiently transfected NHEK 
cells (III).  
 
Figure 9 Localization of CCHCR1 at the centrosome. The first figure illustrates the 
adjacent localization of Iso1Non-risk CCHCR1 (stable cell line) with the C-terminal 
pDsRed tag to the controsomal marker γ-tubulin. The next two figures illustrate the 
colocalization of the endogenous CCHCR1 (stained with an antibody tagging the N-
terminus) with the γ-tubulin. Nuclear staining is also observable in the HEK293 figure. The 
last figure shows the localization of CCHCR1, in transiently transfected NHEK cells, at the 
centrosome. Scale bar: 10 μm. Modified from III. 
Despite the absence of DsRed-tagged CCHCR1 isoforms (tag in the C-terminus) 
in the following locations, the endogenous protein (stained with an antibody 
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against the N-terminal part of isoform 3) was detectable also at the cell-cell 
borders and spots in the nucleus (III). IEM revealed labeling in the close proximity 
of cell membranes in association with desmosomes both in psoriatic and healthy 
skin samples. These additional locations suggested that the C-terminus was 
modified or cleaved. Western blot supported the modification: an additional band 
with smaller size was seen under the full-length sized CCHCR1 band. 
6.3. CCHCR1 affects cytoskeleton, cell morphology, and cell cycle (III, IV) 
The stable overexpression of CCHCR1 affected the morphology of the HEK293 
cells; isoforms 1 and 3 having opposing effects on the size and shape. Iso1Non-
risk CCHCR1 affected the cell size and shape to appear bigger and rounder, than 
the other cell lines. Both isoform 3-expressing cell lines appeared smaller than the 
isoform 1-expressing cells and had more membrane protrusions and also smaller 
nuclei in interphase (P<10−6). The Iso1Non-risk cell line, especially, also exhibited 
multilobular nuclei, suggesting aberrations in cell division. (III) 
We also studied the relationship between CCHCR1 and the cytoskeleton (III). We 
focused on the microtubulus network, as its organization is regulated by the 
centrosome, alongside with actin, vimentin, and cytokeratins. We used 
nocodazole to disrupt the microtubule structures in the overexpressing cell lines, 
which increased the number of cytoplasmic CCHCR1 granules. CCHCR1 was 
observable in the centrosome as well, suggesting that the localization was 
partially dependent on the microtubules. The disruption also affected the 
attachment and shape of the Iso3Risk cells, which clumped together. The isoform 
3 -overexpressing cells exhibited also abnormalities in the actin cytoskeleton, 
especially after the disruption of the microtubules: the actin forms punctate 
staining in the cytoplasm. Vimentin intermediate filaments were only slightly 
altered and lacked similar alterations in organization as actin, after the 
nocodazole treatment 
IF and WB showed downregulation of cytokeratin expression especially in the 
Iso3Risk cells. Downregulation of the cytokeratins was observed also in the 
CCHCR1-silenced HEK293 cell lines. We focused on a specific cytokeratin, KRT17, 
which in the overexpressing CCHCR1 cell lines revealed increased expression by 
IF in Iso1Non-risk cells. The isoform 3 cells, however, showed expression only in 
a few cells. The expression levels were verified with WB and qPCR. Furthermore, 
the silencing of CCHCR1 downregulated the expression of KRT17. Stimulation 
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with EGF induced the expression in all the other cell lines, except in the isoform 3 
-overexpressing and silenced ones. 
As the morphology of the different CCHCR1 overexpressing cell lines already 
suggested, the RNA-seq of the CCHCR1 overexpressing cell lines confirmed that 
there were changes in gene expressions related to cell adhesion; downregulated 
genes of the Iso1Risk and the isoform 3 -overexpressing cell lines were enriched 
for example in focal adhesion pathway. 
CCHCR1 isoform 3 -overexpressing cells differed from the other cell lines by 
proliferating more vigorously; we counted the cell number with an automated 
cell counter after growth period of 1 or 2 days and determined that the cell 
number was 40–60% higher. We measured the cell proliferation also with a DNA 
stain-based cell proliferation assay that, however, did not reveal any statistically 
significant differences. Differences in the size of nuclei may have an effect on cell 
proliferation methods based on DNA staining. We measured the cell cycle profiles 
or the overexpressing cell lines with FACS analysis. The analysis results lacked 
evidence of the effects of CCHCR1 overexpression on the cell cycle, except for 
apoptosis, which was significantly higher in the Iso3Risk cells, especially after 
synchronization by microtubules network disruption (P<0.03). Transcriotome 
profiling with RNA-seq, however, identified upregulation of cell cycle-related 
pathways especially in the Iso1Non-risk overexpressing cell line, which exhibited 
signs of disturbed cell division in the form of multinucleated nuclei. Proliferation 
and cell cycle analysis of CCHCR1-silenced shRNA-cell lines was also measured 
but lacked significant effects. 
6.4. CCHCR1 regulates EGF-induced STAT3 phosphorylation (III) 
We investigated the effect of epidermal growth factor (EGF) stimulation on the 
HEK293 cells with stable CCHCR1 overexpression or downregulation. The 
stimulation induced the CCHCR1 overexpression even further and affected its 
localization; CCHCR1 was still present at the centrosome but its cytoplasmic 
localization increased. The increase in expression was detected both on RNA and 
protein level (III). Both of the CCHCR1 isoforms 1 and 3, with Non-risk or Risk 
haplotype, responded to the EGF treatment. As EGF activates STAT3, we studied 
also the effects of CCHCR1 isoforms on the phosphorylation of STAT3 by 
immunoblotting, using antibodies against tyrosine 705 or serine 727 
phosphorylated and lysine 685 acetylated STAT3. The isoform 1 overexpression 
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induced the STAT3 tyrosine 705 phosphorylation, whereas isoform 3 lacked the 
same effect. The effect was induced even further when stimulated with EGF. In 
addition, the silencing of CCHCR1 decreased the activation. Expression level of 
STAT3 and its serine 727 phosphorylation or lysine 685 acetylation remained 
unaffected. 
6.5. CCHCR1 affects the expressions profile of cultured cells with haplotypic 
effects (IV) 
We assessed gene expression profiles of the CCHCR1 overexpressing HEK293 cell 
lines by RNA-seq. All the four different forms (Iso1Non-risk, Iso1Risk, Iso3Non-
risk, and Iso3Risk) were compared with the expression levels in the controls, 
including wild type HEK293 (WT) and Vector (V). Several genes were 
upregulated and downregulated and the different forms had an effect on many 
different genes but also all shared 209 upregulated (FC>1.5) and 618 
downregulated (FC<0.75) genes (FDR<0.25). We used the DEGs for functional and 
pathway analysis. Upregulated functions included: regulation of transcription 
(genes containing zinc finger domains), and protein phosphorylation by 
serine/threonine kinases. Interestingly, negative regulation of transcription from 
RNA polymerase II promoter was among the functions as well. Downregulated 
genes also enriched in functional categories related to transcriptional regulation 
but also blood vessel morphogenesis and genes with EGF calcium binding 
domain were highlighted. The downregulated genes were also enriched in 
calcium signaling and regulation of actin cytoskeleton pathways.  
7. RNA-seq exhibits similar pathways and functions in psoriatic skin 
and in cells with disturbed gene expression by CCHCR1-
manipulation (IV) 
We compared the expression profiles of the psoriatic SGs and the CCHCR1-
overexpressing or silenced cell lines. The two different study groups shared 
functions and pathways. Notably, as we described in the psoriasis study (II), the 
NLR and RLR signaling pathways were upregulated. In the CCHCR1-
overexpressing cell lines, however, the pathways were downregulated. We 
compared all the DEGs from the overexpressing cell lines with the DEGs from the 
psoriasis SGs. The two groups shared 1962 DEGs that in the GO analysis were 
enriched in functions and pathways related to e.g. metabolism of proteins, 
signaling by Wnt, mitochondria, gene expression, cell cycle, and infections. 
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Interestingly, humanin-like genes, encoding an anti-apoptotic peptide that was 
mentioned in the RNA-seq of non-lesional psoriatic skin, were among the DEGs 
detected by RNA-seq. The RNA-seq of overexpressing cell lines identified several 
other nuclear homologs of MTRNR2, of which MTRNR2L7 was highly 
downregulated in Iso1Risk and in both isoform 3 -overexpressing cells. 
Table 4 Main results of CCHCR1 functions studied in this thesis 
Function Effect 
Regulation of 
cytoskeleton 
Alterations in the cell morphology 
   Cytokeratin Iso1N upregulates expression; especially KRT17, which is 
upregulated also by iso1R. Iso3 and CCHCR1 silencing inhibits 
expression 
   Actin Isoform-specific effect of CCHCR1 on the actin cytoskeleton and 
the overexpression affects the regulation of actin cytoskeleton 
pathway. Actin forms punctate staining in iso3R after disruption 
of the microtubulus cytoskeleton 
   Vimentin Downregulated especially in the iso3 -overexpressing cells 
Size of the nucleus Biggest in iso1N, whereas smaller in iso3 cells. Iso1N exhibits also 
increased number of large cells with multilobulated nulei 
Proliferation Iso3 cells multiply faster than Iso1 cells or controls 
Cell death Iso3R cells exhibit larger population of dying, possibly apoptotic, 
cells 
STAT3 
phosphorylation 
P-Tyr upregulated in iso1 cells, iso3 and downregulation of 
CCHCR1 inhibits phosphorylation even when stimulated by EGF 
Localization of P-
bodies  
P-bodies colocalize rarely with iso1, whereas iso3 colocalize with 
P-bodies, also at the centrosome 
1/iso1; isoform 1, 3/iso3; isoform 3, N; non-risk, R; risk, P-Tyr; tyrosine phosphorylation 
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DISCUSSION  
1. STRT RNA sequencing with spike-in normalization  
The STRT RNA-seq method, complemented with the synthetic spike-in RNAs, 
revealed variation in polyA+ RNA content per total RNA in different cell types; 
skin grafts of normal and psoriatic skin and cultured keratinocytes and HaCaT 
cells. Even though the STRT reads arise from the ultimate 5’ end of the polyA+ 
transcripts and the method lacks information on the splice variants, the 
advantages include especially the identification of transcription start sites and 
strand information (Islam et al., 2012; Swindell et al., 2014). The small amount of 
starting material needed for library preparation, early multiplexing, and the 
inclusion of external spike-in RNAs as a standard procedure can also be included 
as advantages. The spike-in normalization has been shown to be a valuable tool 
when comparing samples with fluctuating polyA+ RNA contents (Katayama et 
al., 2013; Loven et al., 2012) and we showed that it produced consistent results 
with qPCR validations. KCs have been shown to change their RNA content over 
time in long-term culture (Staiano-Coico et al., 1986) and here we showed that the 
tissue samples differed from the cultured cells. The approach is applicable also 
for other studies with fluctuating polyA+ RNA content, here it was suitable for 
the transcriptome study on the CCHCR1-overexpressing cell lines that also had 
variation on their cell size and thus total RNA content. 
2. Transcriptional profiling of psoriatic epidermis 
Several transcriptomics studies have been conducted on psoriatic skin, most of 
them using full-thickness biopsies. Our approach was to focus on the epidermis. 
The results highlighted alterations in functions related to epidermal homeostasis 
in the psoriatic lesional skin and already in the non-lesional skin. The most 
notable difference between the full-thickness and skin graft transcriptomes of 
psoriasis was that lymphocyte, muscle contraction, and secretion were 
highlighted only in the full-thickness samples that contain large amount of dermis. 
Furthermore, it has been suggested that dermis-derived transcripts are driven 
downward by the expansion of epidermis in psoriatic lesions (Li et al., 2014) or 
by gene length bias (Swindell et al., 2014), both of which we took into 
consideration by using the skin graft samples and by the 5’ end targeted RNA-seq 
method.  
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There are only a few transcriptional studies conducted with psoriatic non-lesional 
skin compared with normal skin, this one being the first that focuses on the 
epidermal transcription. We identified 35 differentially expressed transcripts, 
many of which (12 DETs) mapped to the known psoriasis susceptibility loci. 
PSORS4 was the most represented and has been already discovered by previous 
studies (Itoh 2005, Gudjonsson 2009). Most of the upregulated genes in the non-
lesional skin were upregulated also in the lesional samples, except for CNTNAP3B, 
and the mitochondrial transcripts that mostly represent MTRNR2. Among the 
downregulated genes, we identified MTRNR2L1 (humanin-like), which is the 
nuclear gene homolog of MTRNR2 (humanin). The specific quantitation of 
humanin and its homolog was difficult due to high sequence similarity. However, 
we demonstrated that humanin was strongly expressed both in psoriatic and 
healthy skin. Humanin and its homologs are peptides with antiapoptotic and 
cytoprotective activities (Yen et al., 2013; Zapala et al., 2011) but have not been 
implicated in psoriasis or in skin before. Its receptor agonist CALML5 (Hashimoto 
et al., 2013; Mehul et al., 2006), however, has been linked with psoriasis. The role 
of humanin in the pathogenesis of psoriasis remains to be studied.  
The main advantage of RNA-seq in the transcriptome studies is the increased 
sensitivity, which enabled us to identify more DEGs than the previous microarray 
studies. Innate immunity, including NLR signaling and inflammasome activation, 
were highlighted in the analysis from lesional skin. It has been previously shown 
that the key components of the inflammasome are present in keratinocytes 
(Watanabe et al., 2008) and we investigated further the expression of NOD2, 
PYCARD, IFI16, CARD6, and NLRP10 to validate the possible activation of these 
innate immunity-related pathways on protein level. Except for NLRP10, previous 
transcriptome studies (Li et al., 2014; Mitsui et al., 2012) have identified their 
induction in lesional skin. NOD2, a key component of the NLR signaling pathway, 
exhibited induced expression in psoriatic epidermis, especially in keratinocytes. 
Several alleles of NOD2 have been associated with inflammatory diseases, 
including atopic eczema and arthritis (Zhong et al., 2013). Their role in psoriasis, 
however, has not been confirmed (Zhu et al., 2012a). NLRs, such as NOD2, 
NLRP10, and NLRX1, which were upregulated in our lesional samples, operate 
via RIPK2 by regulating the nuclear factor-kB and mitogen-activated protein 
kinase pathways that lead to the production of chemokines, cytokines, and 
antimicrobial peptides (Latz et al., 2013; Zhong et al., 2013). Though highly 
upregulated in lesional skin, the gene CARD6 has not been genetically associated 
58 
 
with psoriasis. Its function is unclear; it may play a role in immune defense via 
interaction with RIPK2 (Dufner et al., 2008). We detected CARD6 in the cytoplasm 
but also in the mitochondria, which is a novel localization for the protein. 
Interestingly, a small fraction of NOD2 is also localized, with another 
inflammasome-related protein; mitochondrial antiviral-signaling protein (MAVS), 
at the mitochondria (Sabbah et al., 2009). Some drugs used for the treatment of 
psoriasis, such as dithranol, function via the mitochondria. The number of 
mitochondria is increased in the psoriatic epidermis and their function altered via 
changes in the cristae when treated with dithranol (Swanbeck and Lundquist, 
1972). The shape of the mitochondrial cristae determines the respiratory efficiency 
and effects on the cell growth via the assembly of the respiratory chain 
supercomplex assembly (Cogliati et al., 2013). 
PYCARD, a key component of the inflammasomes, was upregulated also on 
protein level in our lesional samples. Its location was predominantly cytoplasmic, 
but in some cells also nuclear. Closer investigation of the keratinocytes in the 
lesional samples revealed cytoplasmic PYCARD clusters that may represent 
inflammasomes. Some of the clusters were associated with membrane structures. 
Interestingly, lysosome was most enriched in our pathway analysis and it has 
been shown that lysosome rupture plays a role in NLRP3 inflammasome 
signaling (Jin and Flavell, 2010). In addition, inflammasomes colocalize with 
autophagosomes (Shi et al., 2012). It remains to be studied whether the membrane 
structures in lesional keratinocytes represent lysosomes, autophagosomes, or 
other vacuoles. The genes for the most studied inflammasome receptors, NLRP1 
and NLRP3, were not among the DEGs detected in this study. However, they have 
been associated with psoriasis (Carlstrom et al., 2012; Ekman et al., 2014). NLRP10 
was a novel DEG discovered in our study and we demonstrated that NLRP10 
protein is strongly expressed both in healthy as well as in psoriatic skin. 
Interestingly, NLRP10 has been suggested as an inhibitor of the inflammasome 
assembly (Damm et al., 2013) but essential for the initiation of the adaptive 
immunity by dendritic cells (Eisenbarth et al., 2012)and harbors polymorphisms 
that are associated with atopic dermatitis but not with psoriasis (Hirota et al., 2012; 
Zhong et al., 2013).  
IFI16 was strongly increased in the lesions, and predominantly present in nuclei. 
IFI16 and AIM2, which both were upregulated in the lesional samples, encode for 
DNA-sensing receptors that form an inflammasome with PYCARD (Chiliveru et 
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al., 2014; de Koning et al., 2012a). There is abundant cytoplasmic DNA in 
keratinocytes of psoriatic lesions, and thus DNA-sensing receptors have been 
suggested to play a role in the pathogenesis of psoriasis (Lande et al., 2007; Prens 
et al., 2008). AIM2 is among the most highly upregulated PRRs in lesional skin 
(Prens et al., 2008), which agrees with previous findings that illustrate activation 
of PYCARD by IFI16 already in the cell nucleus (Chiliveru et al., 2014; de Koning 
et al., 2012a). It has been suggested that in psoriastic lesions IFI16 translocates 
from cell nuclei into the cytoplasm in a subpopulation of keratinocytes, whereas 
in non-lesional skin it stays in nuclei (Chiliveru et al., 2014). Our results, however, 
did not support the translocation of IFI16 to the cytoplasm and the most obvious 
difference was strong nuclear staining in lesions, but weaker expression in 
controls. In addition, RNA-sensing receptors IFIH1 and DDX58 (RIGI) were 
induced in the lesional samples and are well known susceptibility genes in 
psoriasis (Oudot et al., 2009). DDX58 operates via inflammasome and there is 
interplay between the RLR and NLR pathways for DDX58 and NOD2 regulate 
each other (Abbott et al., 2007). Our analysis identified also CYLD, a psoriasis 
candidate gene that functions in both pathways (Abbott et al., 2007; Friedman et 
al., 2008; Oudot et al., 2009). 
3. Function of CCHCR1 and relevance in psoriasis 
In the psoriasis susceptibility gene study, we cloned a novel longer isoform 1 
encoding transcript. It is transcribed from an alternative TSS (exon 1b) and the 
SNP (rs3130453) in the following exon 2 determines whether the isoform 1 
translated; a stop codon (*Iso3) inhibits translation and tryptophan (*Iso1) enables 
it. The association analyses of psoriasis samples suggested that the *Iso3 allele, 
which inhibits the translation of the CCHCR1 isoform 1, associates with psoriasis, 
along with previously studied risk allele *WWCC. HLA-Cw6, the main marker of 
PSORS1, is strongly associated with psoriasis. The mechanistic support for its role 
in this disease is missing and since the whole region is in strong linkage 
disequilibrium, the investigation of the function and association of other genes, 
such as CCHCR1, is justified. The role of CCHCR1 as a susceptibility gene for 
psoriasis has been strengthened by genome-wide association studies where the 
SNPs investigated also in this thesis (rs130076 and rs3130453) have shown strong 
association with psoriasis (Liu et al., 2008; Riveira-Munoz et al., 2011; Zhang et al., 
2009; Zheng et al., 2011).  
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The exact cellular localization of CCHCR1 has been undefined, for the expression 
level of the endogenous protein in cells is extremely low and therefore difficult to 
detect. We investigated the localization of CCHCR1 and detected it at the 
centrosome and pericentrosomal region (Figure 10). This novel localization is 
supported by previous mass spectrometry studies, where CCHCR1 was detected 
from extracted centrosomes (Andersen et al., 2003; Jakobsen et al., 2011), and later 
by an immunoprecipitation study where they replicated our pericentrosomal 
localization result in stably overexpressing CHO-K1 cells (Ling et al., 2014). We 
also ensured that the pericentrosomal localization was not merely an aggresome, 
which forms next to the centrosome. This finding was also replicated by Ling et 
al. (Ling et al., 2014). Furthermore, we reported that CCHCR1 colocalizes at the 
centrosome with a phosphorylated form of β-catenin, a protein involved in Wnt 
pathway and implicated in psoriasis (Gudjonsson et al., 2010b). β-catenin has a 
function in cell-cell adhesion and regulates centrosome splitting and microtubule 
re-growth the centrosome (Bahmanyar et al., 2008; Huang et al., 2007; Kaplan et 
al., 2004). 
The centrosome plays an important role in cell division, therefore linking the 
function of CCHCR1 to this event. The localization of CCHCR1 fluctuated during 
the cell cycle and was observable also at the midbody during cytokinesis. Various 
centrosomal proteins, including γ-tubulin and β-catenin, have a function in 
cytokinesis as well and are identifiable at the midbody (Glotzer, 2005; Kaplan et 
al., 2004; Steigemann and Gerlich, 2009). The formation of multilobulated nuclei 
in the CCHCR1 overexpressing cell lines, especially in the CCHCR1-Iso1Non-risk 
cells, also suggests a role in cell division and cytokinesis. The RNA-seq study 
highlighted SYT1, which was highly upregulated in the isoform 3 -overexpressing 
cells. Interestingly, Syt1 has been suggested to associate with the MTOC and plays 
a role in spindle organization in mouse oocytes (Zhu et al., 2012b). IEM of the skin 
samples also revealed that the CCHCR1 is expressed at the proximity of cell 
membrane and desmosomes, which was also observed by IF staining of the 
endogenous CCHCR1 in the cell cultures. Furthermore, it has been shown that 
during epidermal differentiation the desmosomes replace centrosomes and 
become the organizational centers for the microtubules (Lechler and Fuchs, 2007).  
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Figure 10 Possible functions of CCHCR1 in the cell. The figure is based on the literature, 
current interacting profile of CCHCR1, and the results in this thesis. CCHCR1 is suggested 
to play a role in several processes that influence proliferation, differentiation, and cell death. 
It is located in the centrosome, the main center for cell cycle control, and isoform-
specifically in the P-bodies; centrosomal P-bodies control primary cilium formation, which 
suggests participation of CCHCR1 in this process. CCHCR1 has haplotype-specific effects 
on actin cytoskeleton, observed especially when the microtubulai are disrupted. P-bodies 
are linked to microtubules and actin cytoskeleton as well. In addition, P-body protein 
XRN1, which interacts with CCHCR1, regulates microtubule assembly. CCHCR1 interacts 
with mitochondrial StAR and is involved in steroidogenesis. Moreover, mitochondria, P-
bodies, and microtubules interact as well. RPB3 (RNA polymerase II subunit 3) interacts 
with CCHCR1, which acts as its cytoplasmic docking site, therefore controlling 
transcription and differentiation. The RPB3-CCHCR1 interaction may also affect the 
mRNA decay pathway, for it has been shown that RNA polymerase II subunits (RPB4 and 
RPB7) can translocate from nucleus to the cytoplasmic P-bodies. CCHCR1 interacts with 
several viral proteins and P-body components are required for viral cycle completion. P-
body components might also be involved in the host viral defense via interacting with 
several viral RNAs or proteins. We also demonstrated the isoform-specific effect of 
CCHCR1 on STAT3 Tyr705 phosphorylation, which in turn regulates many of the 
processes already mentioned above. Remade and modified from Ling et al. 2014. 
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Centrosome regulates the organization of microtubules, therefore modulating the 
shape and size of the cell (Badano et al., 2005). Stable overexpression of CCHCR1 
resulted in isoform- and haplotype-specific morphological changes in cell size 
and shape. This could be caused by the alterations in the cytoskeleton, which is 
also supported by previous microarray data from transgenic CCHCR1 mice 
(Elomaa et al., 2004). Here we demonstrated that overexpression of CCHCR1 
affects the arrangement and expression of actin, vimentin, and cytokeratins. 
Nocodazole is an agent that inhibits the polymerisation of microtubule filaments 
and the treatment with it affected CCHCR1 expression and localization in the 
stable cell lines, suggesting that microtubules partially regulate CCHCR1 
localization. Disruption of the microtubule cytoskeleton affects the actin 
cytoskeleton for they are dependent on each other (Enomoto, 1996). Interestingly, 
in the isoform 3 -overexpressing cell line, with Risk allele, the effect on actin 
cytoskeleton was seen after disruption of the microtubule cytoskeleton, causing 
formation of actin-rich clusters. The clusters resembled podosomes or 
invadopodia, which are actin-containing structures involved in cell migration and 
invasion. Vimentin is also present in the elongated mature invadopodia 
(Schoumacher et al., 2010). Similar clustering of vimentin after the disruption of 
the microtubules cytoskeleton, however, was not observable in our study. The 
expression of vimentin was downregulated especially in the isoform 3 -
overexpressing cells. Not surprisingly, vimentin is involved in the cell 
proliferation and maintenance of cell shape and its gene expression is 
downregulated in the psoriatic skin (Henno et al., 2009; Lund et al., 2010; Mendez 
et al., 2010; Paccione et al., 2008).  
The shared DEGs from all four overexpressing cell lines, detected by RNA-seq, 
highlighted regulation of actin cytoskeleton and focal adhesion, which were 
downregulated in both Risk cell lines. Several relevant genes, whose expression 
products may disturb cytoskeletal organization, were downregulated especially 
in Iso3Risk cells. These included talin-1 (TLN1) and fibronectin 1 (FN1), which 
were downregulated in Iso1Risk and both isoform 3 -overexpressing cells, 
whereas they were upregulated in the Iso1Non-risk cells. TLN1 plays a significant 
role in the assembly of actin filaments and in spreading and migration of cells and 
indirectly interacts with FN1 (Jiang et al., 2003), which mainly functions in cell 
adhesion (Muro et al., 2003) and was downregulated also in the lesional SG 
samples. Interestingly, CCHCR1 has been also suggested to affect adhesion in 
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psoriatic skin where it was expressed in keratinocytes that had absent 
membranous β-catenin staining (Suomela et al., 2003) 
The expression levels and patterns of various cytokeratins are also changed in the 
psoriatic skin (Henno et al., 2009; Leigh et al., 1995). Previous microarray results 
from transgenic mice suggest that CCHCR1 might regulate the expression of 
cytokeratins (Elomaa et al., 2004). The expression of cytokeratins was decreased 
most prominently in the Iso3Risk-overexpressing cells, which is consistent with 
previous results from experiments with transgenic mice that overexpress 
CCHCR1-Iso3Risk and exhibited the keratins as the most strongly downregulated 
gene group when compared with Iso3Non-risk mice (Elomaa et al., 2004). Here 
we also showed that the overexpression of CCHCR1 affects the expression of 
KRT17, a hallmark and plausible auto-antigen for psoriasis (de Jong et al., 1991; 
Gudmundsdottir et al., 1999; Leigh et al., 1995; Shen et al., 2006). The expression 
of KRT17 was upregulated in the Iso1Non-risk-overexpressing cells and the 
expression was stimulated by EGF in both cell lines overexpressing isoform 1 but 
not in the cell lines overexpressing isoform 3. The silencing of CCHCR1 in 
HEK293 cells downregulated the KRT17 expression. KRT17 is overexpressed in 
the psoriatic lesions and its expression is altered in experiments with transgenic 
mice overexpressing CCHCR1 (de Jong et al., 1991; Elomaa et al., 2004; Leigh et 
al., 1995; Shi et al., 2011). In psoriatic skin, it is suggested to promote epithelial 
proliferation, modulate immune responses, and to have antiapoptotic effects 
(Chang et al., 2011; Depianto et al., 2010). KRT17 is also suggested to regulate cell 
growth and size by promoting protein synthesis (Kim et al., 2006) and therefore 
the upregulation of KRT17 in Iso1Non-risk cells may also cause the increase in 
cell size. 
CCHCR1 has been implicated to play a role in keratinocyte proliferation (Tiala et 
al., 2008), which led us to investigate the role of the different isoforms and 
haplotypes on proliferation. Isoform 3 -overexpression led to faster multiplication 
and with the Risk haplotype also showed slight increase in apoptosis. After 
synchronization the rate of apoptosis increased as the cell cycle progressed, 
suggesting failure to proceed from cell cycle check points, which may result from 
the cytoskeletal aberrations. Measuring proliferation in cells where the cells nuclei 
are varying in size was challenging; methods relying on the amplification of DNA 
could not detect proliferation as the Iso1Non-risk cells seem to form 
multinucleated cells but fail to go through cytokinesis, whereas the size of the 
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nucleus is smaller in the isoform 3 -overexpressing cells that divide more 
vigorously, but as in the case of Iso3Risk cells, also fail to propagate further and 
go to apoptosis. Interestingly, the expression of anti-apoptotic peptide encoding 
humanin-like genes were among the DEGs detected by RNA-seq.  
The localization of CCHCR1 is thus dynamic and it traffics between the 
centrosome and cytoplasm. CCHCR1 was recently identified as a component of 
cytoplasmic P-bodies that regulate various posttranscriptional processes (Ling et 
al., 2014). P-bodies are cytoplasmic sites for regulation of mRNA turnover in a 
post-transcriptional manner and their major functions involve mRNA 
degradation and surveillance, translational repression, and RNA-mediated gene 
silencing (Eulalio et al., 2007). Interestingly, cytoplasmic P-bodies are able to 
traffic to and from the centrosome, along microtubules, and some stationary P-
bodies even reside at the centrosome (Aizer et al., 2008; Moser et al., 2011). We 
verified the location for both CCHCR1 isoforms but observed isoform-specific 
effects on the P-body localization (unpublished data). The isoform 1 -
overexpressing cells, especially Non-risk, illustrated only occasional 
colocalization of CCHCR1 with the P-body markers, whereas the isoform 3 -
overexpressing cells exhibited clear colocalization. The interaction with P-body 
marker EDC requires the N-terminus of CCHCR1 isoform 3 (Ling et al., 2014). 
Isoform 1 is 89 amino acids longer than isoform 3, at its N-terminus. Therefore, 
the additional amino acids might affect the localization of the P-bodies at the 
centrosome. Interestingly, GO analysis from the RNA-seq data illustrated 
enrichment of DEGs specific to the isoform 3 -overexpressing cells on 
transcription regulation. RNA degradation and mRNA surveillance pathway 
were upregulated especially in the Iso3Non-risk cells. Interestingly, negative 
regulation of transcription from RNA polymerase II promoter was among the 
upregulated functions that were shared in all the cell lines overexpressing 
CCHCR1, which is supported by the interaction of CCHCR1 with its subunit 
RPB3 (Corbi et al., 2005).  Moreover, RPB3 regulates the expression and 
compartmentalization of vimentin (Corbi et al., 2010), which implicates that the 
effect of CCHCR1 on vimentin organization could also be mediated through its 
interaction with RPB3. 
Our results from the stable cell lines strengthen previous findings that implicate 
regulation of the EGFR-STAT3 signaling pathway by CCHCR1. It has been also 
previously shown that EGF stimulates CCHCR1 expression in HaCaT cells and in 
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skin cancer CCHCR1 and EGF receptor (EGFR) are expressed in same areas (Tiala 
et al., 2007). In transgenic mice, the expression of constitutively active Stat3 leads 
to a psoriasis-like skin phenotype and the keratinocytes within psoriatic skin are 
characterized by activated STAT3 (Sano et al., 2005; Sano et al., 2008). Here we 
showed that EGF treatment induces the expression of CCHCR1 in the stably 
overexpressing CCHCR1 cell lines, both on mRNA and protein level. 
Interestingly, EGF is known to stimulate the expression of several genes, such as 
β-catenin and thrombospondin-1, through post-transcriptional mechanisms (Lee 
et al., 2010; Okamoto et al., 2002). We suggest that the increase in CCHCR1 
expression is based both on mRNA and protein stabilization. We also showed that 
CCHCR1 regulates EGF-induced STAT3 phosphorylation in an isoform-specific 
manner: STAT3 tyrosine 705 phosphorylation was disturbed in the isoform 3 -
overexpressing cells, whereas the CCHCR1 isoform 1 slightly activated the STAT3 
phosphorylation, even without EGF-induction. The RNA-seq experiment, 
however, exhibited upregulation of ErbB signaling mainly in the Iso3Non-risk 
cells and downregulation in Risk cells. ErbB signaling is linked to psoriasis in 
several studies (Ainali et al., 2012; Piepkorn et al., 2003) and was enriched also in 
our lesional SG samples. AREG encodes a protein that belongs to the EGF family 
and binds EGFR as well. It associates with a psoriasis-like skin phenotype 
(Schneider et al., 2008), shows increased protein expression in lesional skin 
(Piepkorn, 1996), and might be affecting the integrity of cell–cell junctions in 
psoriasis (Chung et al., 2005). In our overexpressing cell lines, AREG was 
upregulated in the Iso1Non-risk cells and might also drive the STAT3 
phosphorylation. 
The silencing of CCHCR1 in HEK293 cells decreased the tyrosine 705 
phosphorylation. Tyrosine 705 phosphorylation of STAT3 is suggested to be 
crucial for its nuclear translocation (Amin et al., 2004; Reich and Liu, 2006). 
Constitutive activation of STAT3 in psoriatic skin may result from the persistent 
stimulation of EGFR for its multiple ligands, including HB-EGF, are increased in 
psoriatic skin (Sano et al., 2008; Schneider et al., 2008; Yoshida et al., 2008b). 
STAT3 regulates various processes, such as cell proliferation, differentiation, 
apoptosis, and differentiation of the TH17 helper T cells, in the skin (Sano et al., 
2008; Yang et al., 2007). Interestingly, KRT17 expression is also upregulated by 
STAT3 (Shi et al., 2011), suggesting that the induction of KRT17 in HEK293 cells 
overexpressing CCHCR1 isoform 1 with Non-risk allele, is regulated through this 
pathway. Furthermore, STAT3 also controls post-transcriptional processes and 
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modulates centrosome doubling by regulating γ-tubulin levels (Metge et al., 2004). 
Furthermore, it also regulates cell migration directly by binding stathmin, a 
depolymerization agent of microtubules (Ng et al., 2006). 
We compared the expression profiles of the psoriatic SGs and the CCHCR1-
overexpressing cell lines to illustrate further the link between CCHCR1 and 
psoriasis. The two different study groups shared several functions and pathways, 
including the above-mentioned EGF receptor signaling pathway. In addition, the 
shared DEGs were enriched in functions and pathways related to e.g. metabolism 
of proteins, Wnt and MAPK signaling, apoptosis, and cell cycle, most of which 
are well described in psoriasis. Pathways associated with innate immunity were 
highlighted as well, including the RLR and NLR signaling pathway and pathways 
related to infections. IL8, an important mediator of the immune reaction in the 
innate immune system response, was induced in the isoform 1 -overexpressing 
cells. Furthermore, IL8 and STAT3 regulate each other in certain conditions, 
including psoriasis (de la Iglesia et al., 2008; Kanda et al., 2011; Zhang et al., 2012). 
The pathogenic link between the immune system and CCHCR1, in cultured 
keratinocytes, was also suggested in the earlier studies, where IFN-γ was shown 
to downregulate CCHCR1 expression. Interestingly, P-bodies are as well 
associated with innate immunity via colocalization with apolipoprotein B mRNA 
editing enzyme APOBEC3G (Wichroski et al., 2006), which was downregulated 
especially in the cells with overexpression of CCHCR1 isoform 3, with the Risk 
haplotype. APOBEC family of proteins has been suggested to play a role in innate 
anti-viral immunity (Takaori, 2005) and the gene APOBEC3A was highly 
upregulated in our psoriasis lesional samples.  
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CONCLUSIONS AND FUTURE PROSPECTS 
RNA-seq, with RNA spike-in normalization, revealed more accurate expression 
profiling in different sample types with varying amounts of RNA. Combined with 
the use of skin graft samples it allowed improved recognition of altered 
transcripts, functions, and pathways in psoriasis. Compared with the previous 
transcriptomics studies on psoriasis, our approach provided more information 
about the transcriptional dysregulation in the epidermis. A deeper understanding 
on the components of NOD-like receptor signaling pathway and inflammasome 
activation in keratinocytes is a good example of the sensitivity of the method. 
Some of the components have been associated with psoriasis in previous studies, 
yet the exact composition and activation mechanisms of inflammasomes in 
psoriasis have remained unclear. Our RNA-seq and immunostainings strengthen 
previous findings on psoriasis, suggesting that all components needed for the 
active inflammasome are present in keratinocytes of the epidermis and are 
activated in the lesional skin. The inflammasome type and factors leading to its 
activation in psoriasis, however, remain to be determined. The 5’ end RNA-seq 
method allows the precise determination of transcription start sites as well. 
Therefore, whether aberrant gene expression patterns that promote the 
pathogenesis of psoriasis arise from alternative promoter usage, remains to be 
investigated.   
Here we presented that CCHCR1 localizes at the centrosome and verified its 
localization in the P-bodies. Our experiments show haplotype-specific effects of 
CCHCR1 on cytoskeletal organization and cell proliferation, functions relevant to 
the pathogenesis of psoriasis (Figure 11). Furthermore, our results suggest that 
CCHCR1 might function in EGFR-STAT3 signaling and innate immunity, which 
are functions previously implicated in psoriasis as well. In addition, the RNA-seq 
revealed isoform and haplotype-specific effects on expression profiles of different 
CCHCR1 cell lines, which strengthens the role of CCHCR1 as an effector gene in 
the pathogenesis of psoriasis. Furthermore, CCHCR1 plays a role in several 
pathways that have been associated with psoriasis. Interestingly, the most 
dramatic changes in gene expression were observable in the isoform 3 -
overexpressing cells but also the Non-risk and Risk alleles had opposing effects. 
The observation that CCHCR1 influences multiple cell signaling pathways may 
result from its possible role as a centrosomal P-body protein, which suggests a 
role in post-transcriptional regulation as well as a role in regulation of the cell 
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cycle. Its exact function in these cellular compartments and effect in psoriatic 
lesions remains to be studied further. The identification of dysregulated pathways 
in the psoriatic epidermis and the cellular functions of the psoriasis candidate 
gene CCHCR1 could provide information for novel medications, plausibly 
targeting the innate immunity pathways. 
 
Figure 11 Summary of the main conclusions in this thesis. In this thesis, we genotyped a 
novel SNP that enables the translation of a longer isoform (Iso1) and redefined the 
psoriasis-associated haplotype of CCHCR1 as *Iso3WWCC. This suggests that, in some of 
the psoriasis patients, the absence of isoform 1 might have an effect on the onset or the 
propagation of the disease, in addition to the previously described Risk (*WWCC) 
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haplotype. In functional studies of CCHCR1, indeed, had isoform-specific effects on e.g. 
proliferation, which is the main characteristics of the disease. In healthy skin, CCHCR1 is 
expressed in the keratinocytes at the basal layer of the epidermis. In the thickened psoriatic 
epidermis, its expression is altered: it is expressed also in supra-basal layers above the tip 
of the dermal papillae. We found that its localization is dynamic in the cell and it locates 
especially at the centrosome, and additionally at the P-bodies, while possibly having an 
isoform-specific effect on their localization in the cell. Both centrosomes and P-bodies are 
physically connected to the cytoskeleton that functions as a scaffold for the regulation of 
e.g. mRNA turnover, cell division, cell adhesion, and transport of organelles, such as 
mitochondria. Our previous results and the present RNA-seq suggest that CCHCR1 
regulates expression of cytoskeletal components and functions related to cytoskeleton, 
such as cell adhesion. These functions, such as regulation of actin cytoskeleton, werealtered 
also in our RNA-seq of the psoriatic skin. Furthermore, CCHCR1 may control the mRNA 
turnover at P-bodies by regulating RNA surveillance and degradation. This may affect a 
wide variety of diverse biological processes. RNA-seq identified several pathways for 
CCHCR1 which are relevant for the pathogenesis of psoriasis, such as epidermis 
development, Wnt, ErbB, and MAPK signaling, and innate immunity. The RNA-seq of 
psoriatic lesional epidermis highlighted the importance of the activation of the innate 
immunity pathways in the keratinocytes. In addition, our RNA-seq of the non-lesional skin 
of the psoriasis patients redefined the upregulation of PSORS4-derived transcripts.  
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